
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            The Transthyretin/Oleuropein Aglycone Complex: A New Tool against TTR Amyloidosis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="8E59B38D925F94633AB38D00462452AF.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="pharmaceuticals">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8953266/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Pharmaceuticals">
<meta name="citation_title" content="The Transthyretin/Oleuropein Aglycone Complex: A New Tool against TTR Amyloidosis">
<meta name="citation_author" content="Francesco Bemporad">
<meta name="citation_author_institution" content="Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale Morgagni 50, 50134 Florence, Italy; francesco.bemporad@unifi.it (F.B.); matteo.ramazzotti@unifi.it (M.R.); massimo.stefani@unifi.it (M.S.); monica.bucciantini@unifi.it (M.B.)">
<meta name="citation_author" content="Manuela Leri">
<meta name="citation_author_institution" content="Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale Morgagni 50, 50134 Florence, Italy; francesco.bemporad@unifi.it (F.B.); matteo.ramazzotti@unifi.it (M.R.); massimo.stefani@unifi.it (M.S.); monica.bucciantini@unifi.it (M.B.)">
<meta name="citation_author" content="Matteo Ramazzotti">
<meta name="citation_author_institution" content="Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale Morgagni 50, 50134 Florence, Italy; francesco.bemporad@unifi.it (F.B.); matteo.ramazzotti@unifi.it (M.R.); massimo.stefani@unifi.it (M.S.); monica.bucciantini@unifi.it (M.B.)">
<meta name="citation_author" content="Massimo Stefani">
<meta name="citation_author_institution" content="Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale Morgagni 50, 50134 Florence, Italy; francesco.bemporad@unifi.it (F.B.); matteo.ramazzotti@unifi.it (M.R.); massimo.stefani@unifi.it (M.S.); monica.bucciantini@unifi.it (M.B.)">
<meta name="citation_author" content="Monica Bucciantini">
<meta name="citation_author_institution" content="Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale Morgagni 50, 50134 Florence, Italy; francesco.bemporad@unifi.it (F.B.); matteo.ramazzotti@unifi.it (M.R.); massimo.stefani@unifi.it (M.S.); monica.bucciantini@unifi.it (M.B.)">
<meta name="citation_publication_date" content="2022 Feb 23">
<meta name="citation_volume" content="15">
<meta name="citation_issue" content="3">
<meta name="citation_firstpage" content="277">
<meta name="citation_doi" content="10.3390/ph15030277">
<meta name="citation_pmid" content="35337074">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8953266/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8953266/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8953266/pdf/pharmaceuticals-15-00277.pdf">
<meta name="description" content="The release of monomers from the homotetrameric protein transthyretin (TTR) is the first event of a cascade, eventually leading to sporadic or familial TTR amyloidoses. Thus, ligands able to stabilize TTR and inhibit monomer release are subject of ...">
<meta name="og:title" content="The Transthyretin/Oleuropein Aglycone Complex: A New Tool against TTR Amyloidosis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="The release of monomers from the homotetrameric protein transthyretin (TTR) is the first event of a cascade, eventually leading to sporadic or familial TTR amyloidoses. Thus, ligands able to stabilize TTR and inhibit monomer release are subject of ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8953266/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="8953266">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.3390/ph15030277"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/pharmaceuticals-15-00277.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC8953266%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/8953266/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/8953266/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC8953266/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-pharmaceuticals.png" alt="Pharmaceuticals logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Pharmaceuticals" title="Link to Pharmaceuticals" shape="default" href="http://www.mdpi.com/journal/pharmaceuticals" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Pharmaceuticals (Basel)</button></div>. 2022 Feb 23;15(3):277. doi: <a href="https://doi.org/10.3390/ph15030277" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.3390/ph15030277</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22Pharmaceuticals%20(Basel)%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pharmaceuticals%20(Basel)%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Pharmaceuticals%20(Basel)%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Pharmaceuticals%20(Basel)%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>The Transthyretin/Oleuropein Aglycone Complex: A New Tool against TTR Amyloidosis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bemporad%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Francesco Bemporad</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Francesco Bemporad</span></h3>
<div class="p">
<sup>1</sup>Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale Morgagni 50, 50134 Florence, Italy; francesco.bemporad@unifi.it (F.B.); matteo.ramazzotti@unifi.it (M.R.); massimo.stefani@unifi.it (M.S.); monica.bucciantini@unifi.it (M.B.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bemporad%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Francesco Bemporad</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Leri%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Manuela Leri</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Manuela Leri</span></h3>
<div class="p">
<sup>1</sup>Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale Morgagni 50, 50134 Florence, Italy; francesco.bemporad@unifi.it (F.B.); matteo.ramazzotti@unifi.it (M.R.); massimo.stefani@unifi.it (M.S.); monica.bucciantini@unifi.it (M.B.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Leri%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Manuela Leri</span></a>
</div>
</div>
<sup>1,</sup><sup>*</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ramazzotti%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Matteo Ramazzotti</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Matteo Ramazzotti</span></h3>
<div class="p">
<sup>1</sup>Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale Morgagni 50, 50134 Florence, Italy; francesco.bemporad@unifi.it (F.B.); matteo.ramazzotti@unifi.it (M.R.); massimo.stefani@unifi.it (M.S.); monica.bucciantini@unifi.it (M.B.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ramazzotti%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Matteo Ramazzotti</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Stefani%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Massimo Stefani</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Massimo Stefani</span></h3>
<div class="p">
<sup>1</sup>Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale Morgagni 50, 50134 Florence, Italy; francesco.bemporad@unifi.it (F.B.); matteo.ramazzotti@unifi.it (M.R.); massimo.stefani@unifi.it (M.S.); monica.bucciantini@unifi.it (M.B.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Stefani%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Massimo Stefani</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bucciantini%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Monica Bucciantini</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Monica Bucciantini</span></h3>
<div class="p">
<sup>1</sup>Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale Morgagni 50, 50134 Florence, Italy; francesco.bemporad@unifi.it (F.B.); matteo.ramazzotti@unifi.it (M.R.); massimo.stefani@unifi.it (M.S.); monica.bucciantini@unifi.it (M.B.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bucciantini%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Monica Bucciantini</span></a>
</div>
</div>
<sup>1</sup>
</div>
<div class="cg p">Editor: <span class="name western">Kwang-Won Lee</span><sup>1</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="af1-pharmaceuticals-15-00277">
<sup>1</sup>Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale Morgagni 50, 50134 Florence, Italy; francesco.bemporad@unifi.it (F.B.); matteo.ramazzotti@unifi.it (M.R.); massimo.stefani@unifi.it (M.S.); monica.bucciantini@unifi.it (M.B.)</div>
<div class="author-notes p"><div class="fn" id="c1-pharmaceuticals-15-00277">
<sup>*</sup><p class="display-inline">Correspondence: <span>manuela.leri@unifi.it</span></p>
</div></div>
<h4 class="font-secondary">Roles</h4>
<div class="p">
<strong class="contrib"><span class="name western">Kwang-Won Lee</span></strong>: <span class="role">Academic Editor</span>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2022 Jan 26; Accepted 2022 Feb 21; Collection date 2022 Mar.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2022 by the authors.</div>
<p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by/4.0/</a>).</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC8953266  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35337074/" class="usa-link">35337074</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>The release of monomers from the homotetrameric protein transthyretin (TTR) is the first event of a cascade, eventually leading to sporadic or familial TTR amyloidoses. Thus, ligands able to stabilize TTR and inhibit monomer release are subject of intense scrutiny as potential treatments against these pathologies. Here, we investigated the interaction between TTR and a non-glycated derivative of the main olive polyphenol, oleuropein (OleA), known to interfere with TTR aggregation. We coupled fluorescence studies with molecular docking to investigate the OleA/TTR interaction using wild-type TTR, a monomeric variant, and the L55P cardiotoxic mutant. We characterized a fluorescence band emitted by OleA upon formation of the OleA/TTR complex. Exploiting this signal, we found that a poorly specific non-stoichiometric interaction occurs on the surface of the protein and a more specific stabilizing interaction takes place in the ligand binding pocket of TTR, exhibiting a <em>K<sub>D</sub></em> of 3.23 ± 0.32 µM, with two distinct binding sites. OleA interacts with TTR in different modes, stabilizing it and preventing its dissociation into monomers, with subsequent misfolding. This result paves the way to the possible use of OleA to prevent degenerative diseases associated with TTR misfolding.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> transthyretin, polyphenols, systemic amyloidosis, misfolding</p></section></section><section id="sec1-pharmaceuticals-15-00277"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Transthyretin (TTR), also known as prealbumin, is a 55 KDa circulating protein produced by liver and, to a lesser extent, by choroid plexus, with a well-established role in the transport of thyroxine (T4) and retinol in the plasma and the cerebrospinal fluid [<a href="#B1-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B1-pharmaceuticals-15-00277">1</a>]. Structurally, TTR is a homotetramer, where the four monomers are assembled with a 2:2:2 symmetry resulting in a dimer of dimers. In each dimer, monomer interaction is stabilized through H-bonds involving the two-edge H and F β-strands; the back-to-back association of the two dimers is stabilized by a limited number of contacts, giving rise to two symmetrical binding sites for T4, at the dimer–dimer interface [<a href="#B2-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B2-pharmaceuticals-15-00277">2</a>]. According to computational analysis, human TTR possesses a relatively high intrinsic propensity to β-aggregation [<a href="#B3-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B3-pharmaceuticals-15-00277">3</a>], and such a propensity is strongly enhanced in a set of genetic TTR variants as a result of a destabilization of the native TTR structure [<a href="#B4-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B4-pharmaceuticals-15-00277">4</a>].</p>
<p>Presently, over 130 TTR gene mutations have been associated with pathological phenotypes, with autosomal dominant inheritance [<a href="#B5-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B5-pharmaceuticals-15-00277">5</a>,<a href="#B6-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B6-pharmaceuticals-15-00277">6</a>,<a href="#B7-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B7-pharmaceuticals-15-00277">7</a>,<a href="#B8-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B8-pharmaceuticals-15-00277">8</a>]. Under proper conditions, wild-type TTR (wt-TTR) or TTR variants polymerize into amyloid fibrils in vivo, similarly to over 30 other known peptides/proteins involved in different amyloid diseases. Most of the reported TTR mutations result in loss of tetramer stability, with tetramer dissociation into misfolded monomers and dimers that undergo aberrant partial refolding with generation of amyloidogenic intermediates [<a href="#B9-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B9-pharmaceuticals-15-00277">9</a>]. Importantly, a strong correlation does exist between the thermodynamic/kinetic stability of TTR variants and their propensity to grow into misfolded, soluble and insoluble aggregates [<a href="#B10-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B10-pharmaceuticals-15-00277">10</a>,<a href="#B11-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B11-pharmaceuticals-15-00277">11</a>]. Considering the importance of TTR tetramer stability and the structure of the monomer, an engineered monomeric variant of TTR (M-TTR) has been generated. M-TTR is a F87M/L110M double mutant rationally designed to modify the monomer–monomer interface, such that tetramer formation under physiological conditions is hindered [<a href="#B12-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B12-pharmaceuticals-15-00277">12</a>]. </p>
<p>The different forms of senile or familial systemic TTR amyloidosis (A-TTR) are characterized by the presence, in the affected tissues/organs, of extracellular deposits of amyloid fibrils composed of TTR polymers. A-TTR include senile systemic amyloidosis (SSA), familial amyloid cardiomyopathy (FAC), familial amyloid polyneuropathy (FAP), and central nervous system selective amyloidosis (CNSA). SSA is a common, age-related, amyloidosis characterized by the accumulation of wt-TTR fibrils [<a href="#B1-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B1-pharmaceuticals-15-00277">1</a>], predominantly in the heart and, to a lesser extent, in other organs [<a href="#B13-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B13-pharmaceuticals-15-00277">13</a>,<a href="#B14-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B14-pharmaceuticals-15-00277">14</a>]. Depending on the type of A-TTR, the clinical features of these pathologies include a diffuse polyneuropathy, a severe form of cardiomyopathy, or severe neurological symptoms; the latter include seizures, stroke-like episodes, dementia, psychomotor deterioration, hydrocephalus, spinal cord infarction, and variable amyloid deposition in the vitreous humor. In addition to the peripheral nerves and the myocardium, pathological amyloid deposits of TTR are detected in the walls of leptomeningeal vessels and the surrounding connective tissue structures, as well as in the pia arachnoid and subpial region, with risk of cerebral infarction and, in later stages, cerebral hemorrhage [<a href="#B5-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B5-pharmaceuticals-15-00277">5</a>,<a href="#B15-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B15-pharmaceuticals-15-00277">15</a>]. In particular, a severe form of FAP, characterized by early-onset and rapid progressive amyloidosis with severe cardiac involvement (FAC), results from amyloid deposits in the heart parenchyma of a number of mutants, particularly the highly amyloidogenic Leu55Pro (L55P) mutant [<a href="#B16-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B16-pharmaceuticals-15-00277">16</a>,<a href="#B17-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B17-pharmaceuticals-15-00277">17</a>,<a href="#B18-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B18-pharmaceuticals-15-00277">18</a>].</p>
<p>A-TTR are severe diseases due to the substantial lack of effective therapies other than symptomatic ones, and also since their progression is already in an advanced stage when their signs and symptoms appear. In addition, the increased aging of the population potentially fosters the cases of amyloidosis involving wt-TTR (SSA). Accordingly, if coupled to the pharmacological tools presently available, early diagnosis and prevention are important to slow disease progression and to improve its prognosis.</p>
<p>Recently, different approaches targeting amyloid deposits and interfering with organ damage have been developed that are being tested in clinical trials (see later). The results of these ongoing trials, together with a better understanding of the amyloidogenic process and an improved knowledge of the mechanisms of organ damage, will help to establish the role of novel agents and to identify potential alternative therapeutic targets.</p>
<p>The usefulness of exploiting stabilizers of the tetrameric structure of TTR avoiding its disassembly has led us, in recent years, to develop molecules, such as diflunisal and Tafamidis, that associate with and stabilize TTR by occupying the central cavity of the tetramer normally designed to harbor T4. Preclinical studies and clinical trials have supported the protection by these molecules against disease occurrence [<a href="#B19-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B19-pharmaceuticals-15-00277">19</a>]. Diflunisal is an off-label treatment option whose use has limitations due to its non-steroidal anti-inflammatory drug (NSAID) properties [<a href="#B20-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B20-pharmaceuticals-15-00277">20</a>]. Tafamidis stabilizes both wt-TTR and 14 TTR variants clinically tested, as well as 25 TTR variants tested ex vivo [<a href="#B21-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B21-pharmaceuticals-15-00277">21</a>]. Presently, Tafamidis is the first Food and Drug Administration (FDA) and European Medicines Agency (EMA)-approved targeted treatment for TTR cardiomyopathy (ATTR-CM). More recently, other molecules have been developed; these include AG10, a small molecule TTR stabilizer [<a href="#B22-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B22-pharmaceuticals-15-00277">22</a>], and PRX004, the first investigated intravenous immunotherapy drug for treatment of A-TTR (<a href="https://clinicaltrials.gov/ct2/show/NCT03336580" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/ct2/show/NCT03336580</a>; accessed on 20 January 2022). Patisiran and Inotersen are silencers of TTR mRNA that have been approved by FDA for TTR polyneuropathy. These molecules work to prevent translation and to reduce TTR production by hepatocytes [<a href="#B23-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B23-pharmaceuticals-15-00277">23</a>]. Patisiran is a small interfering RNA (siRNA) that targets the 3′ untranslated region of TTR mRNA, causing TTR mRNA degradation through RNA interference [<a href="#B24-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B24-pharmaceuticals-15-00277">24</a>]. Inotersen reduces TTR production by binding to TTR mRNA, with ensuing reduction in serum TTR levels and TTR deposits in tissues (<a href="https://www.ema.europa.eu/en/medicines/human/EPAR/tegsedi" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ema.europa.eu/en/medicines/human/EPAR/tegsedi</a>; accessed on 20 January 2022). Other molecules able to interfere with TTR production, unfolding, and aggregation presently under investigation include TTR fibril disrupters such as doxycycline, which target amyloid deposits to prevent further tissue damage [<a href="#B23-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B23-pharmaceuticals-15-00277">23</a>].</p>
<p>In this context, several natural polyphenols have been reported to interfere with the misfolding of several amyloidogenic proteins and to inhibit their aggregation into amyloid. In particular, attention has been focused on some flavonoids [<a href="#B25-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B25-pharmaceuticals-15-00277">25</a>] and natural polyphenols in relation to their ability to bind and to stabilize TTR, hindering its fibrillization. The most investigated plant polyphenols include resveratrol [<a href="#B26-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B26-pharmaceuticals-15-00277">26</a>], curcumin [<a href="#B27-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B27-pharmaceuticals-15-00277">27</a>], epigallocatechin 3-gallate (EGCG) [<a href="#B28-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B28-pharmaceuticals-15-00277">28</a>], and more recently, oleuropein aglycone (OleA), the main phenolic component of the extra virgin olive oil [<a href="#B29-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B29-pharmaceuticals-15-00277">29</a>]. Notably, an EGCG preparation (GTE) is a nonpharmacological option that is used for the treatment of ATTR-CM [<a href="#B23-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B23-pharmaceuticals-15-00277">23</a>].</p>
<p>Most of the studies reported above have shown that all these compounds stabilize TTR and inhibit its aggregation by strongly suppressing tetramer dissociation, maintaining protein solubility [<a href="#B28-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B28-pharmaceuticals-15-00277">28</a>,<a href="#B29-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B29-pharmaceuticals-15-00277">29</a>], or alternatively, by inducing TTR oligomerization into a homogeneous population of small off-pathway non-toxic aggregates [<a href="#B30-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B30-pharmaceuticals-15-00277">30</a>]. We previously reported that OleA does not inhibit aggregation of both wt-TTR and L55P-TTR; rather, it reduces the exposure of protein aromatic residues during the amyloidogenic process. We found that the presence of OleA during non-native aggregation under acid conditions of wt-TTR and L55P-TTR induced an increase in Trp quenching; this finding suggests that the stabilization by OleA of meta-stable misfolded intermediates of TTR relies on the reduction in their surface hydrophobicity. Overall, the data reported suggest that OleA induces some remodeling of the supramolecular structure of the growing aggregates [<a href="#B29-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B29-pharmaceuticals-15-00277">29</a>].</p>
<p>Although our previous work highlighted the ability to alter aggregation exerted by OleA, those data were collected under non-physiological acidic conditions. Consequently, in the present study, we further investigated the TTR-OleA relation by analyzing in depth the native interaction between OleA and different forms of TTR (wt-TTR, L55P-TTR and M-TTR) under physiological conditions to improve the knowledge, at a molecular level, of both the anti-amyloidogenic activity of this polyphenol and the underlying molecular mechanisms. These aspects are of great importance to assess the possible use of this plant polyphenols as natural TTR stabilizers to prevent the onset of different sporadic and familial TTR amyloidosis. Indeed, a deeper knowledge of the OleA-TTR interaction is a prerequisite to devise new therapeutic strategies aimed at exploiting these natural compounds, alone or in combination with other molecular treatments, to prevent A-TTR and other amyloid-associated diseases.</p></section><section id="sec2-pharmaceuticals-15-00277"><h2 class="pmc_sec_title">2. Results</h2>
<section id="sec2dot1-pharmaceuticals-15-00277"><h3 class="pmc_sec_title">2.1. Molecular Docking of Polyphenols to Native TTR</h3>
<p>We carried out molecular docking experiments to explore the possible ability of small molecules, namely Oleuropein (Ole), Oleuropein aglycone (OleA), T4, and resveratrol, to bind the crystal structure of the biologically active wt-TTR and its mutant L55P-TTR. Autodock-Vina was asked to suggest the 20 best poses showing a difference of at most 3 Kcal/mol from the best and the worst pose. In a free-to-bind (i.e., not indicating a specific docking area) experiment, T4 was correctly located into the already-described C2 symmetric funnel-shaped T4 binding site at the dimer–dimer interface (<a href="#pharmaceuticals-15-00277-f001" class="usa-link">Figure 1</a>), with a binding energy of −5.9 Kcal/mol. The interaction of resveratrol in the same site was even stronger (−6.3 Kcal/mol). On the contrary, the best pose of Ole was not in the main funnel; rather, it was localized in the secondary funnel, identified as the halogen binding site [<a href="#B31-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B31-pharmaceuticals-15-00277">31</a>]. However, removal of the sugar moiety from Ole led OleA to interact with the main funnel very strongly (−7.7 Kcal/mol), thus displaying the highest affinity in this experimental set-up.</p>
<figure class="fig xbox font-sm" id="pharmaceuticals-15-00277-f001"><h4 class="obj_head">Figure 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8953266_pharmaceuticals-15-00277-g001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed0/8953266/e03c420b2e8c/pharmaceuticals-15-00277-g001.jpg" loading="lazy" height="483" width="712" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/pharmaceuticals-15-00277-f001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Orthogonal side views of the TTR tetramer binding OleA in the best (most stable) pose, as determined by molecular docking experiments performed with Autodock-Vina.</p></figcaption></figure><p>We then repeated the docking simulation by specifically testing the penetration into, and the binding to, the main funnel of the investigated molecules. T4 penetrated deeper in the funnel than in the previous setup, although with a lower interaction energy (−5.0 Kcal/mol). The opposite behavior was observed when studying resveratrol, which penetrated less deeply but with a stronger interaction energy (−7.6 Kcal/mol). Ole interaction in the tested main funnel was deep and with a docking energy slightly lower than resveratrol (−7.4 Kcal/mol). Again, OleA exhibited the highest interaction energy (−8.1 Kcal/mol).</p>
<p>Given the cooperative nature of T4 binding to TTR, we also checked whether the previously tested, ligand-free TTR was not sufficiently prepared to host ligands (considering that, during docking, the involved part of the protein is considered as a rigid body). Therefore, we repeated the experiments with a different crystal structure of TTR, where the main funnel was originally bound to T4, allowing the protein to be considered in an “open” state. We prepared this new experiment by removing T4 from the main funnel and repeated the analysis as before. This time, all tested molecules spontaneously (i.e., without targeting) docked into the main funnel, and OleA displayed the highest affinity (−8.8 Kcal/mol), followed by resveratrol (−6.9 Kcal/mol), T4 (−6.3 Kcal/mol), and Ole (−6.0 Kcal/mol). Thus, when tested in silico, OleA exhibits an affinity for the TTR binding pocket comparable to, if not higher than, the affinities displayed by other known ligands.</p></section><section id="sec2dot2-pharmaceuticals-15-00277"><h3 class="pmc_sec_title">2.2. Excitation−Emission Matrices</h3>
<p>We then investigated the OleA-wt-TTR interaction in vitro by recording fluorescence emission–excitation matrices, using fluorescence wavelengths in the 280–340 nm range for excitation and in the 350–600 nm range for emission. <a href="#pharmaceuticals-15-00277-f002" class="usa-link">Figure 2</a> shows that the excitation–emission matrix of OleA alone did not reveal detectable fluorescence emission; the matrix obtained for wt-TTR displayed the intrinsic fluorescence typical of a buried tryptophan upon excitation in the 280–310 nm range, namely a band centered at 335 nm and no emission at higher wavelengths (<a href="#pharmaceuticals-15-00277-f002" class="usa-link">Figure 2</a>b). Interestingly, we observed a different behavior when OleA and TTR were incubated together for 24 h at a concentration of 15 µM and 5.0 µM, respectively. In this case, a previously undetected signal appeared, located between 400 and 450 nm. This signal could not be observed when OleA or TTR were present alone in solution, making this band a possible candidate to investigate the interaction between these two species.</p>
<figure class="fig xbox font-sm" id="pharmaceuticals-15-00277-f002"><h4 class="obj_head">Figure 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8953266_pharmaceuticals-15-00277-g002.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed0/8953266/a68e40cc6253/pharmaceuticals-15-00277-g002.jpg" loading="lazy" height="248" width="760" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/pharmaceuticals-15-00277-f002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Excitation−emission matrices (EEM) in the 280–340 nm excitation range and in the 350--600 nm emission range. The samples tested were (<strong>a</strong>) OleA, (<strong>b</strong>) wt-TTR, and (<strong>c</strong>) the complex wt-TTR/OleA incubated at pH 7.0 and 37 °C for 24 h. In all matrices, the white-colored band on the bottom right corner corresponds to the harmonic (double wavelength) of the incoming light, which gives an intense signal that reaches the top-scale; the small yet detectable signal in the top left corner (emission–excitation coordinates going from 350–315 to 400–340 nm) corresponds to the Raman scattering of water.</p></figcaption></figure></section><section id="sec2dot3-pharmaceuticals-15-00277"><h3 class="pmc_sec_title">2.3. Investigation of the Interaction between OleA and wt-TTR</h3>
<p>Following our initial observation of a so far undetected fluorescence band in the 400–450 nm range emitted by OleA in the presence of TTR, we sought to exploit this signal to extract quantitative information about the interaction between the two molecules. In a first experiment, we evaluated the fluorescence measured at a constant concentration of OleA, in the presence of increasing concentrations of wt-TTR. The fluorescence spectra, reported in <a href="#pharmaceuticals-15-00277-f003" class="usa-link">Figure 3</a>a, indicate that the fluorescence intensity of OleA was substantially unaffected at protein concentrations below 0.1 µM (<a href="#pharmaceuticals-15-00277-f003" class="usa-link">Figure 3</a>a), whereas at protein concentrations &gt;0.1 µM, the signal displayed two effects; first, the signal increased as the wt-TTR concentration increased (<a href="#pharmaceuticals-15-00277-f003" class="usa-link">Figure 3</a>a). The total fluorescence emitted by OleA in the presence of 100 µM wt-TTR was 10.6 ± 1.5 times higher than the signal emitted in the presence of 10 nM wt-TTR. Second, the signal displayed a blue shift that was more evident as the concentration of wt-TTR increased. The peak wavelengths of OleA were 435 or 413 nm in the presence of 10 nM or 100 µM wt-TTR, respectively. To highlight this effect, we normalized the spectra to the signal emitted at 420 nm (<a href="#pharmaceuticals-15-00277-f003" class="usa-link">Figure 3</a>b).</p>
<figure class="fig xbox font-sm" id="pharmaceuticals-15-00277-f003"><h4 class="obj_head">Figure 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8953266_pharmaceuticals-15-00277-g003.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed0/8953266/79f9c362bdd2/pharmaceuticals-15-00277-g003.jpg" loading="lazy" height="675" width="724" alt="Figure 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/pharmaceuticals-15-00277-f003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>OleA-wt-TTR interaction. (<strong>a</strong>) Fluorescence emission spectra of OleA in the presence of increasing concentrations of wt-TTR in the 1 × 10<sup>−8</sup> M-10<sup>−4</sup> M range. The color varies from blue to purple as the protein concentration increases from 1 × 10<sup>−8</sup> M to 1 × 10<sup>−4</sup> M, as shown in the color scale. (<strong>b</strong>) The same spectra shown in panel (<strong>a</strong>), normalized to the signal emitted at 420 nm to highlight the blue shift of the emission we observed on increasing wt-TTR concentration. Color scale as in panel (<strong>a</strong>). (<strong>c</strong>) Total emission intensities of the spectra reported in panel (<strong>a</strong>) plotted vs. wt-TTR concentration. The concentration refers to the tetramer. Color scale as in panel (<strong>a</strong>). (<strong>d</strong>) The fraction of wt-TTR bound to OleA plotted vs. wt-TTR concentration. The concentration refers to the tetramer. We calculated the fraction bound from the analysis of the blue shift of the emission, as reported in the Methods section. Color scale as in panel (<strong>a</strong>).</p></figcaption></figure><p>To extract a dissociation constant <em>(K<sub>D</sub></em>) value for the OleA-TTR complex from the fluorescence data, we plotted total OleA fluorescence vs. wt-TTR concentration (<a href="#pharmaceuticals-15-00277-f003" class="usa-link">Figure 3</a>c). The results of this analysis confirmed the increase in the signal observed on increasing wt-TTR concentration. However, the trace obtained did not reach a plateau, even at wt-TTR concentrations in the 10–100 µM range, the maximum protein concentration we could reach in our experimental setting. Consequently, we could not extract a quantitative parameter from these data. When we considered the emission wavelength, a different trend was observed. In fact, the fluorescence spectra began to exhibit a significant blue shift at wt-TTR concentrations above 0.1 µM, and this shift reached a plateau starting from 40 µM. We could observe a plateau by plotting either the center of mass (COM) or the ratio between the fluorescence at 428 and 413 nm (<a href="#app1-pharmaceuticals-15-00277" class="usa-link">Supplementary Figure S1</a>). This trend is suggestive of a binding process that begins at protein concentrations above 0.1 µM and reaches saturation at protein concentrations above 40 µM. Consequently, the data reported in <a href="#pharmaceuticals-15-00277-f003" class="usa-link">Figure 3</a>d were normalized to the bound fraction, i.e., the fraction of OleA bound to wt-TTR under a certain condition. We plotted the bound fraction vs. protein concentration (<a href="#pharmaceuticals-15-00277-f003" class="usa-link">Figure 3</a>d) and fitted the data to a binding equilibrium, as reported in the Methods section. The outcome of this analysis yielded a <em>K</em><sub>D</sub> value of 3.23 ± 0.32 µM. Thus, our data show that it is possible to exploit the fluorescence emitted by OleA in the presence of wt-TTR to gauge affinity parameters.</p></section><section id="sec2dot4-pharmaceuticals-15-00277"><h3 class="pmc_sec_title">2.4. Investigation of the Interaction between OleA and TTR Mutants</h3>
<p>For comparison with the data obtained with wt-TTR, the same experiment was repeated in the presence of two TTR mutants, L55P-TTR and M-TTR. Indeed, the binding pocket is known to be altered in the L55P variant and absent in M-TTR. The emission spectra of 0.5 µM OleA recorded in the presence of different concentrations of the two variants are shown in <a href="#app1-pharmaceuticals-15-00277" class="usa-link">Supplementary Figure S2a</a>, where the spectra measured in the presence of the two variants at 100 µM protein concentration are compared with that of wt-TTR. These spectra illustrate that the two mutant proteins induced a different effect when compared to wt-TTR; in fact, the blue shift shown by OleA in the presence of L55P-TTR was much less intense than that observed with wt-TTR (<a href="#pharmaceuticals-15-00277-f004" class="usa-link">Figure 4</a>a). Indeed, the emission peak shifted from 431.2 nm to 425.2 nm upon increasing L55P-TTR concentration from 0.01 to 100 µM, a 6.0 nm shift that was much lower than the 22 nm shift observed with wt-TTR (<a href="#pharmaceuticals-15-00277-f004" class="usa-link">Figure 4</a>b). Although the reduced shift observed made the data noisier, we attempted a quantitative analysis to calculate the OleA-L55P-TTR affinity constant, as reported above for wt-TTR. The analysis yielded a <em>K<sub>D</sub></em> value of 3.12 ± 0.62 µM, which is, within the experimental error, substantially identical to the affinity calculated for wt-TTR. When the M-TTR data were analyzed, we found that this variant was unable to induce any significant shift of OleA emission. In fact, even at low protein concentration, the emission of OleA occurred at slightly shorter wavelengths that with wt-TTR: the peak was present at 426 nm even in the presence of M-TTR concentrations as low as 0.01 µM. However, the peak remained in the same position even when the protein concentration was increased up to values of 195 µM, the maximum concentration we could reach.</p>
<figure class="fig xbox font-sm" id="pharmaceuticals-15-00277-f004"><h4 class="obj_head">Figure 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8953266_pharmaceuticals-15-00277-g004.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed0/8953266/21c5438c4f0d/pharmaceuticals-15-00277-g004.jpg" loading="lazy" height="1572" width="694" alt="Figure 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/pharmaceuticals-15-00277-f004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Interaction between OleA and TTR mutants. (<strong>a</strong>) Comparison between the emission of OleA at a concentration of 0.5 µM in the presence of 100 µM wt-TTR (black), L55P-TTR (red), and M-TTR (blue). The inset shows a magnification of the spectrum recorded in the presence of M-TTR. (<strong>b</strong>) Peak wavelength of the OleA spectra as a function of the concentration of wt-TTR (black), L55P-TTR (red), and M-TTR (blue). (<strong>c</strong>) Total fluorescence emitted by OleA as a function of the concentration of wt-TTR (black), L55P-TTR (red), and M-TTR (blue).</p></figcaption></figure><p>A different trend was observed when the emission intensity was taken into consideration (<a href="#app1-pharmaceuticals-15-00277" class="usa-link">Supplementary Figure S2</a> and <a href="#pharmaceuticals-15-00277-f004" class="usa-link">Figure 4</a>c). In fact, both mutants were able to induce an increase in the emission of OleA, yet with different intensities. The total emission values in the presence of 100 µM protein were 42,800, 31,100, and 5600 a.u. for wt-TTR, L55P-TTR, and M-TTR, respectively. However, it is important to point out that the concentrations shown in <a href="#pharmaceuticals-15-00277-f004" class="usa-link">Figure 4</a>c are molar concentrations. Given the monomeric nature of M-TTR, the different ability of OleA to induce fluorescence increases may be at least partially compensated for by normalizing the data to the mass concentration. This mathematical operation would reduce the emission intensities of the tetrameric wt-TTR and L55P-TTR by four times.</p></section><section id="sec2dot5-pharmaceuticals-15-00277"><h3 class="pmc_sec_title">2.5. Biophysical Characterization of the Emission by OleA</h3>
<p>The change in OleA fluorescence we observed remains elusive and cumbersome to interpret. The question arises as to whether the observed changes of emission correspond to a true binding event and whether or not this binding occurs within the binding site of TTR, or rather, it results from a non-specific interaction at the protein surface. Therefore, to better interpret our data, we made a series of measurements of OleA fluorescence. First, we investigated OleA emission in the presence of β-cyclodextrin (βCD), a cyclic oligosaccharide containing seven glucose molecules with a hydrophilic outer surface and a hydrophobic inner cavity, known to be able to harbor phytochemicals [<a href="#B32-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B32-pharmaceuticals-15-00277">32</a>]. We measured the emission of OleA in water, in the absence or in the presence of an identical molar concentration of βCD (<a href="#pharmaceuticals-15-00277-f005" class="usa-link">Figure 5</a>a). We found that the emission of OleA displayed increased intensity and a blue shift in the presence of βCD. In fact, the total fluorescence emitted in the presence of βCD was 3.3 ± 0.1 times higher than that measured in the absence of the molecule. As far as the emission wavelength is concerned, we measured peak wavelengths of 459 and 485.2 nm in the presence and in the absence of βCD, respectively.</p>
<figure class="fig xbox font-sm" id="pharmaceuticals-15-00277-f005"><h4 class="obj_head">Figure 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8953266_pharmaceuticals-15-00277-g005.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed0/8953266/8adc4773a138/pharmaceuticals-15-00277-g005.jpg" loading="lazy" height="1638" width="679" alt="Figure 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/pharmaceuticals-15-00277-f005/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Biophysical characterization of the fluorescence emitted by OleA. (<strong>a</strong>) Fluorescence spectra of 200 µM OleA recorded in water in the absence (black) or in the presence (blue) of 200 µM β-cyclodextrin. (<strong>b</strong>) OleA emission peak as a function of solvent relative permittivity (ε/ε<sub>0</sub>). The inset shows a comparison between the OleA emission spectra recorded in water (ε/ε<sub>0</sub> = 79.4) (black) or in propanol (ε/ε<sub>0</sub> = 21.8) (red). (<strong>c</strong>) Comparison of total OleA fluorescence intensity measured in the presence of 100 µM hen egg white lysozyme (HEWL), bovine serum albumin (BSA), or wt-TTR.</p></figcaption></figure><p>Next, to possibly assign the emission of OleA to the effect of a hydrophobic chemical environment, we measured the fluorescence spectra of OleA in different solvents with varying relative permittivity (ε/ε<sub>0</sub>) (<a href="#pharmaceuticals-15-00277-f005" class="usa-link">Figure 5</a>b). When we plotted the peak wavelength vs. ε/ε<sub>0</sub>, a significant blue shift was observed upon increasing the hydrophobicity. In fact, in water (ε/ε<sub>0</sub> = 80) the peak was present at 485.2 nm, whereas in 1-buthanol (ε/ε<sub>0</sub> = 17.5), the peak was located at 433.7 nm, leading us to establish a direct link between the hydrophobicity of the chemical environment and the observed blue shift.</p>
<p>We also investigated whether the ability to induce an increase in OleA fluorescence was a specific feature of TTR or, rather, it was shared with other proteins. A series of samples containing OleA in the presence of the same concentration (100 µM) of different proteins, hen egg white lysozyme (HEWL), bovine serum albumin (BSA) and wt-TTR were investigated. The fluorescence intensities at 485 nm of these samples were measured and normalized at the value observed in the absence of proteins (<a href="#pharmaceuticals-15-00277-f005" class="usa-link">Figure 5</a>b). The results of this experiment are rather complex to elucidate. HEWL did not induce any significant increase in fluorescence intensity of OleA. The signal in the presence of 100 µM HEWL was 1.16 ± 0.17 times higher than that measured in the absence of protein. However, in the presence of BSA, we observed a completely different effect: the signal was 24.7 ± 1.5 times higher than that measured for OleA alone. This increase was greater than that recorded in the presence of an identical amount of wt-TTR. Indeed, we observed that the signal in the presence of 100 µM wt-TTR was 10.6 ± 1.5 times higher than that measured without the protein. We conclude that the ability to induce an increase in OleA fluorescence is not a specific feature of TTR; rather, it is a property shared by TTR with other, but not all, proteins. Probably, the increased effect we observed depends on surface properties —mainly in terms of hydrophobicity—of the investigated protein.</p>
<p>Finally, we investigated the effect of OleA binding on the thermodynamic stability of TTR by means of urea-induced equilibrium unfolding experiments in the presence and in the absence of 100 µM OleA (<a href="#pharmaceuticals-15-00277-f006" class="usa-link">Figure 6</a>). The tryptophan fluorescence spectra were collected and the data were analyzed as reported in the Methods section. The results of this analysis indicate that, in the case of wt-TTR, OleA binding induced a slight, yet significant, increase in the thermodynamic stability of the protein. The free energy change upon unfolding (<span xmlns:mml="http://www.w3.org/1998/Math/MathML"><math id="mm1" overflow="linebreak"><mrow><mrow><mo>Δ</mo><msubsup><mi>G</mi><mrow><mi>U</mi><mo>−</mo><mi>F</mi></mrow><mrow><msub><mi>H</mi><mn>2</mn></msub><mi>O</mi></mrow></msubsup></mrow></mrow></math></span>) were 22,600 ± 200 and 21,800 ± 200 J/mol in the presence and in the absence of OleA, respectively. Different results were obtained with L55P-TTR and M-TTR. The values of <span xmlns:mml="http://www.w3.org/1998/Math/MathML"><math id="mm2" overflow="linebreak"><mrow><mrow><mo>Δ</mo><msubsup><mi>G</mi><mrow><mi>U</mi><mo>−</mo><mi>F</mi></mrow><mrow><msub><mi>H</mi><mn>2</mn></msub><mi>O</mi></mrow></msubsup></mrow></mrow></math></span> obtained for L55P-TTR were 23,000 ± 300 and 22,800 ± 300 J/mol in the absence and in the presence of the ligand, respectively, whereas the values of <span xmlns:mml="http://www.w3.org/1998/Math/MathML"><math id="mm3" overflow="linebreak"><mrow><mrow><mo>Δ</mo><msubsup><mi>G</mi><mrow><mi>U</mi><mo>−</mo><mi>F</mi></mrow><mrow><msub><mi>H</mi><mn>2</mn></msub><mi>O</mi></mrow></msubsup></mrow></mrow></math></span> obtained for M-TTR were of 20,400 ± 200 and 20,200 ± 200 J/mol in the absence and in the presence of the ligand, respectively. This experiment further supports the pieces of evidence concerning TTR-OleA interaction. Ligand binding to the wild-type protein induces an increase in the thermodynamic stability of the tetramer. However, L55P-TTR has a compromised binding pocket that alters the binding, leaving protein stability unaffected by the interaction. We also found that M-TTR is unable to bind OleA and, accordingly, we could not detect any significant effect on the thermodynamic stability of the protein in the presence of the ligand.</p>
<figure class="fig xbox font-sm" id="pharmaceuticals-15-00277-f006"><h4 class="obj_head">Figure 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8953266_pharmaceuticals-15-00277-g006.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed0/8953266/f5738c531baf/pharmaceuticals-15-00277-g006.jpg" loading="lazy" height="222" width="775" alt="Figure 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/pharmaceuticals-15-00277-f006/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Equilibrium unfolding experiments of TTR in the absence (black) and in the presence (red) of 100 µM OleA. Data reported refer to wt-TTR (<strong>left</strong>), L55P-TTR (<strong>center</strong>), and M-TTR (<strong>right</strong>). Continuous lines represent best fits of data to the model edited by Santoro and Bolen [<a href="#B33-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B33-pharmaceuticals-15-00277">33</a>].</p></figcaption></figure></section><section id="sec2dot6-pharmaceuticals-15-00277"><h3 class="pmc_sec_title">2.6. Effects of Oleuropein Aglycone on TTR under Physiological Conditions</h3>
<p>Our previous data showed that OleA interacts specifically in the tryptophan (Trp) region of TTR during the aggregation process, under acidic conditions [<a href="#B29-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B29-pharmaceuticals-15-00277">29</a>]. In the present study, we analyzed the effect of OleA on the native tetrameric structure of wt-TTR, L55P-TTR, and M-TTR under physiological conditions (pH 7.0). The data obtained by the equilibrium unfolding were confirmed by the analysis of TTR intrinsic fluorescence in the presence or in the absence of OleA at different incubation times (<a href="#pharmaceuticals-15-00277-f007" class="usa-link">Figure 7</a>). Second derivate spectra showed two peaks at around 330 nm and 350 nm that are associated with different polarities of the environment surrounding aromatic residues due to the presence, in each TTR monomer, of two Trp residues at positions 41 and 79. The 330 nm peak, typical of the natively folded protein with buried indole moieties, is the most evident, whereas the less intense 350 nm peak is due to the contribution of the solvent-exposed Trp. In our experimental setting, we found that the two peaks were unaffected by the presence of OleA, also after protein incubation for 72 h, confirming that the OleA/TTR interaction does not affect the structure of the native protein.</p>
<figure class="fig xbox font-sm" id="pharmaceuticals-15-00277-f007"><h4 class="obj_head">Figure 7.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8953266_pharmaceuticals-15-00277-g007.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed0/8953266/6188d5640c3e/pharmaceuticals-15-00277-g007.jpg" loading="lazy" height="523" width="789" alt="Figure 7"></a></p>
<div class="p text-right font-secondary"><a href="figure/pharmaceuticals-15-00277-f007/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Intrinsic fluorescence emission spectra recorded at different times of incubation of wt-TTR (<strong>a</strong>), L55P-TTR (<strong>e</strong>), and M-TTR (<strong>i</strong>) before and after OleA supplementation to the incubation mixture (<strong>b</strong>,<strong>f</strong>,<strong>l</strong>). The spectra were normalized to fluorescence intensity of 1.0 at λ<sub>max</sub>, λ<sub>exc</sub> = 295 nm. (<strong>c</strong>,<strong>d</strong>,<strong>g</strong>,<strong>h</strong>,<strong>m</strong>,<strong>n</strong>). The second derivatives were obtained from the previous emission spectra.</p></figcaption></figure></section></section><section id="sec3-pharmaceuticals-15-00277"><h2 class="pmc_sec_title">3. Discussion</h2>
<p>The knowledge of the mechanism by which polyphenolic compounds interfere with amyloid aggregation is of great importance, considering that (i) the growth of amyloid assemblies is a common feature of many systemic and neurodegenerative diseases, including type 2 diabetes, FAP, FAC, AL-amyloidosis, Alzheimer’s disease, Parkinson’s disease, Creutzfeldt–Jakob’s disease, Huntington’s disease, and many others; (ii) a large number of studies indicate that these molecules are able to interfere in several ways with protein misfolding and the ensuing growth of amyloid assemblies; and (iii) the selection and development of small molecules able to inhibit, or to interfere with, the growth of toxic protein assemblies, most often unstable pre-fibrillar aggregates, or to reduce their ability to bind to the cell membrane could have a considerable clinical application. Therefore, establishing the mechanism by which polyphenols disrupt aggregation-prone conformations is of paramount importance to reach a complete knowledge of the structure–activity relationships of these natural compounds. Recent papers suggest that aromatic interactions favor molecular recognition of amyloidogenic sequences by enhancing the directionality and orientation needed for the ordered self-assembly process and hence fibril assembly kinetics [<a href="#B34-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B34-pharmaceuticals-15-00277">34</a>].</p>
<p>It has been reported that several polyphenols interact with amyloidogenic aromatic residues hindering the stacking of π-systems [<a href="#B35-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B35-pharmaceuticals-15-00277">35</a>,<a href="#B36-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B36-pharmaceuticals-15-00277">36</a>], thus inhibiting the elongation phase of fibril growth or the assembly of large oligomers without interfering with early nucleation events [<a href="#B37-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B37-pharmaceuticals-15-00277">37</a>]. In particular, many natural polyphenols, including resveratrol [<a href="#B38-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B38-pharmaceuticals-15-00277">38</a>], OleA [<a href="#B29-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B29-pharmaceuticals-15-00277">29</a>], curcumin [<a href="#B39-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B39-pharmaceuticals-15-00277">39</a>], and EGCG [<a href="#B30-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B30-pharmaceuticals-15-00277">30</a>], have been reported to inhibit the fibrillogenesis process of amyloid precursor proteins and peptides in vitro and, possibly, in vivo. We previously reported that OleA hinders the amyloid aggregation of both wt-TTR- and L55P-TTR [<a href="#B29-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B29-pharmaceuticals-15-00277">29</a>]. In particular, we observed that OleA significantly reduces solvent exposure of those aromatic residues that become uncovered following tetramer disassembly and the ensuing misfolding of the resulting monomers/dimers. All previous published data were collected under acidic conditions, providing an environment suitable to induce tetrameric TTR destabilization, a condition required to trigger the subsequent amyloid aggregation process.</p>
<p>To better interpret previously published data, in the present study, we sought to investigate the molecular features underlying OleA interaction with the structure of tetrameric TTR under physiological conditions (pH 7.0) for each variant. For the first time, we observed that OleA undergoes fluorescence emission following incubation with TTR. This is not surprising, considering that, even in the case of resveratrol and its main metabolites, the fluorescence spectra of these molecules have been used to assess their ability to interact with TTR [<a href="#B40-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B40-pharmaceuticals-15-00277">40</a>]. The interaction between OleA and TTR induced two distinct effects on OleA fluorescence: an increased fluorescence intensity and a blue shift, even though these phenomena seemed to occur at different protein concentrations. The emission shift appeared at concentrations of wt-TTR higher than 10<sup>−7</sup> M and was complete at 40 µM. The signal enhancement became evident above 10<sup>−6</sup> M and did not reach a plateau at 100 µM, the maximum protein concentration we could reach. A plot displaying the blue shift of OleA fluorescence, assessed as the ratio between the signals at 413 and 428 nm, vs. fluorescence intensity illustrates these observations, suggesting that these events may be the spectroscopic signature of two different processes, which appear in the plot as two distinct linear regions (<a href="#app1-pharmaceuticals-15-00277" class="usa-link">Supplementary Figure S3</a>). Our biophysical investigation allows the blue shift to be assigned to a binding mode, whereby one OleA molecule occupies the binding site of TTR: at low protein concentration, OleA is free in solution and solvent relaxation induces a red shift in the emission of OleA. Indeed, we could obtain a similar blue shift when OleA was incubated with βCD, a molecule providing a hydrophobic cage. Furthermore, the same blue shift was obtained in hydrophobic solvents and the docking studies corroborate this binding mechanism.</p>
<p>As far as the signal increase at high protein concentrations is concerned, it must be noted that this increase was obtained in the presence of different proteins Furthermore, even M-TTR, although devoid of quaternary structure and thus of the binding pocket, exhibited a significant, yet lower, ability to increase OleA fluorescence. These two pieces of evidence suggest that the increase in fluorescence may be due to a non-specific interaction of OleA at the protein surface, rather than to a specific binding in the TTR binding site. However, the fluorescence increase did not reach a plateau at protein concentrations at which the first binding event was saturated and, consequently, no more OleA molecules could still be available under these conditions. A possible explanation of this result is that one OleA molecule interacts with more than one TTR molecule, although the second interaction displays a lower affinity.</p>
<p>The interaction modes described for the first time in the present work are novel but not unique, considering that several small compounds interact with the TTR surface inducing tetramer stabilization and impairing amyloid fibril formation [<a href="#B28-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B28-pharmaceuticals-15-00277">28</a>]. Among these molecules, natural <em>flavonoids, such as EGCG,</em> do not bind at the T4 binding site and stabilize the tetrameric structure by a stable interaction at the surface of each TTR monomer [<a href="#B28-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B28-pharmaceuticals-15-00277">28</a>]. In particular, EGCG binds at the dimer–dimer interface, with a resulting effect similar to that of a cross-linker [<a href="#B41-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B41-pharmaceuticals-15-00277">41</a>]. Our results indicate that OleA binds both at the main funnel and at the hydrophobic surfaces of TTR. Considering the very low toxicity of EGCG and OleA, it would be possible to suggest, and to investigate, the existence of a synergistic effect between these two, and possibly other, polyphenols; the latter could be <em>an </em>encouraging strategy to increase the stabilizing effects of wild-type and mutant forms of TTR by plant polyphenols. </p>
<p>Our data suggest that OleA displays a <em>K<sub>D</sub></em> of ~3.0 uM for wt-TTR, a value similar to that reported for other polyphenols, such as curcumin (<em>K<sub>D</sub></em>~2.0 uM [<a href="#B42-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B42-pharmaceuticals-15-00277">42</a>,<a href="#B43-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B43-pharmaceuticals-15-00277">43</a>]). These values are higher than those reported for drugs used for TTR-amyloidosis such as Tafamidis (4.4 ± 1.3 nM [<a href="#B44-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B44-pharmaceuticals-15-00277">44</a>]) and Diflunisal (407 ± 35 nM [<a href="#B44-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B44-pharmaceuticals-15-00277">44</a>]), but this may be not relevant. In fact, Miller and co-workers reported that the <em>K</em><sub>D</sub> value is not an essential parameter to define a good molecule able to reduce TTR amyloidogenicity [<a href="#B44-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B44-pharmaceuticals-15-00277">44</a>]. In their study, they analyzed the <em>K</em><sub>D</sub> values of different drugs such as AG10, Tafamidis, Diflunisal, and Tolcapone and showed that the efficiency of these drugs does not correlate with their <em>K</em><sub>D</sub> value; rather, it is related to their binding enthalpy values [<a href="#B44-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B44-pharmaceuticals-15-00277">44</a>]. These data agree with the energy value reported for OleA obtained with the DOCKING assay, where OleA displayed the highest affinity and interaction energy. A different, yet weak, interpretation is that the surface interaction we identified may play an important role with respect to the inhibition of aggregation. Indeed, we previously showed that OleA alters the aggregation pathway, leading to the formation of off-pathway oligomeric assemblies [<a href="#B29-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B29-pharmaceuticals-15-00277">29</a>]. An interaction occurring at the protein surface seems more suitable to interfere with intermolecular interactions than a binding event occurring within the protein structure. Consequently, the synergistic effect of the two interaction modes described here may underlie the biological activity of OleA.</p></section><section id="sec4-pharmaceuticals-15-00277"><h2 class="pmc_sec_title">4. Materials and Methods</h2>
<section id="sec4dot1-pharmaceuticals-15-00277"><h3 class="pmc_sec_title">4.1. Oleuropein Deglycosylation</h3>
<p>Oleuropein was purchased from Extrasynthese and deglycosilated by treatment with almond β-glycosidase (EC 3.2.1.21, Fluka, Sigma-Aldrich, St. Louis, MI, USA), as previously described [<a href="#B45-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B45-pharmaceuticals-15-00277">45</a>]. Briefly, a 10 mM solution of oleuropein in 310 μL of 0.1 M sodium phosphate buffer, pH 7.0, was incubated with 8.9 I.U. of β-glycosidase overnight at room temperature. The reaction mixture was centrifuged at 18,000 rpm for 10 min to precipitate OleA, which was resuspended in dimethylsulfoxide (DMSO) in stocks at 50 mM concentration. The complete oleuropein deglycosylation was confirmed by assaying the glucose released in the supernatant with a Glucose (HK) Assay kit (Sigma-Aldrich, St. Louis, MI, USA). Stocks of OleA were kept frozen protected from light and were used within the same day once opened.</p></section><section id="sec4dot2-pharmaceuticals-15-00277"><h3 class="pmc_sec_title">4.2. Preparation of TTR Samples</h3>
<p>Recombinant wt-TTR- and L55P-TTR were expressed and purified according to Mangione et al. [<a href="#B46-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B46-pharmaceuticals-15-00277">46</a>]. Lyophilized TTR was dissolved at 1.6 mM in 30 mM sodium phosphate buffer, and pH 7.0. M-TTR was purified as previously reported [<a href="#B12-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B12-pharmaceuticals-15-00277">12</a>]. In brief, the cleared lysate was loaded on a Q-Sepharose High Performance resin (GE Healthcare) and eluted with a sodium chloride gradient. Then, the protein was further purified by gel filtration with a HiLoad 16/600 Superdex 75 pg (GE). The eluted protein was dialyzed against 20 mM potassium phosphate, 150 mM NaCl buffer at pH 7.3 enriched with 2.0 mM DTT.</p></section><section id="sec4dot3-pharmaceuticals-15-00277"><h3 class="pmc_sec_title">4.3. Docking Experiments</h3>
<p>Ligand interaction with the investigated TTR molecules was investigated by molecular docking with the AutoDock Vina software [<a href="#B47-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B47-pharmaceuticals-15-00277">47</a>]. The reference 3D structures for the simulation were 4MRB (PDB code, wt human TTR pH 7.5, biological tetrameric assembly, resolution 1.27 Å) [<a href="#B48-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B48-pharmaceuticals-15-00277">48</a>], 2ROX (PDB code, wt human TTR complexed with T4, 2 Å) [<a href="#B2-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B2-pharmaceuticals-15-00277">2</a>], and 2B14 (PDB code, L55P human amyloidogenic TTR, resolution 2Å) [<a href="#B48-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B48-pharmaceuticals-15-00277">48</a>] that were prepared using pymol (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.) and AutodockTools (ADT) from MGLTools v. 1.5.6 RC3. For 2ROX, the T4 ligand was removed by manually editing the PDB file and eliminating the lines concerning the T4 molecule.</p>
<p>The structures of the ligands were taken from the ZINC database [<a href="#B49-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B49-pharmaceuticals-15-00277">49</a>]. In addition to oleuropein (id 4098348), T4 (thyroxine, id 3830993) and resveratrol (id 6787) were also obtained. The Zinc database structure editor was used to design OleA by removing the glucose moiety from native oleuropein. Then, both protein and ligands were prepared for docking in ADT by adding explicit hydrogen atoms and saving in pdbqt format. For ligands, all possible torsions were enabled.</p>
<p>Docking grids were designed in ADT using as a reference the TTR tetrameric structure coordinates to locate (1) a large area around the tetrameric protein; (2) the crystal-resolved docking site of T4 (main funnel); and (3) the halogen binding sites (secondary funnel). All the files used for docking are available at <a href="https://github.com/matteoramazzotti/papers/2021ttr_dock" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://github.com/matteoramazzotti/papers/2021ttr_dock</a> (accessed on 20 January 2022).</p></section><section id="sec4dot4-pharmaceuticals-15-00277"><h3 class="pmc_sec_title">4.4. Interaction between OleA and wt-TTR</h3>
<p>We prepared 21 samples containing OleA at a concentration of 500 nM and wt-TTR at concentrations in the 10<sup>−8</sup>–10<sup>−4</sup> M range in 20 mM phosphate buffer, pH 7.4, in a total volume of 60 µL. The fluorescence of each sample was recorded using an Agilent Cary Eclipse spectrofluorometer (Agilent Technologies, Santa Clara, CA, USA) equipped with a thermostated cell holder attached to an Agilent PCB 1500 water Peltier system, using a low-volume quartz cuvette (Hellma, Müllheim, Germany). The excitation wavelength was 340 nm, and the fluorescence spectra were collected in the 400 nm–600 nm range. We used excitation and emission slits of 5.0 nm, a PMF signal of 860 V, and a temperature of 25 °C. To analyze the obtained data, the fluorescence of the blank solution was subtracted from each spectrum, and the total fluorescence emitted at each wt-TTR concentration was calculated as the sum of all the fluorescence values of each spectrum. Then, the spectra obtained (<a href="#pharmaceuticals-15-00277-f003" class="usa-link">Figure 3</a>a) were normalized to the signal emitted at 420 nm (<a href="#pharmaceuticals-15-00277-f003" class="usa-link">Figure 3</a>b) to highlight possible emission shifts. Last, for each spectrum, the peak wavelength ratio between the emission at 428 nm and 413 nm and the center of emission (COM) were calculated according to the equation <span xmlns:mml="http://www.w3.org/1998/Math/MathML"><math id="mm4" overflow="linebreak"><mrow><mrow><mi>COM</mi><mo>=</mo><munder><mstyle mathsize="70%" displaystyle="true"><mo>∑</mo></mstyle><mi>i</mi></munder><msub><mi>F</mi><mi>i</mi></msub><mo>/</mo><munder><mstyle mathsize="70%" displaystyle="true"><mo>∑</mo></mstyle><mi>i</mi></munder><mrow><mo>(</mo><mrow><msub><mi>F</mi><mi>i</mi></msub><mo>·</mo><msub><mover accent="true"><mi>ν</mi><mo>¯</mo></mover><mi>i</mi></msub></mrow><mo>)</mo></mrow></mrow></mrow></math></span>, where <span xmlns:mml="http://www.w3.org/1998/Math/MathML"><math id="mm5" overflow="linebreak"><mrow><mrow><msub><mi>F</mi><mi>i</mi></msub></mrow></mrow></math></span> is the signal emitted at a wavenumber <span xmlns:mml="http://www.w3.org/1998/Math/MathML"><math id="mm6" overflow="linebreak"><mrow><mrow><msub><mover accent="true"><mi>ν</mi><mo>¯</mo></mover><mi>i</mi></msub></mrow></mrow></math></span>. The plot of COM and peak wavelength vs. [wt-TTR] was normalized to the fraction of OleA bound to wt-TTR (<a href="#pharmaceuticals-15-00277-f003" class="usa-link">Figure 3</a>d) (bf), and the plot obtained was analyzed with a binding equilibrium of the type TTR + OleA ⇌ TTR∙OleA, where TTR∙OleA denotes the complex between the two molecules. The trace obtained was fitted to an equation
</p>
<table class="disp-formula p" id="FD1-pharmaceuticals-15-00277"><tr><td class="formula"><math id="mm7" display="block" overflow="linebreak"><mrow><mrow><mi>bf</mi><mo> </mo><mo>=</mo><mo> </mo><mn>1</mn><mo>/</mo><mo>{</mo><mn>1</mn><mo> </mo><mo>+</mo><mo> </mo><msub><mi>K</mi><mi>D</mi></msub><mo>/</mo><mo>[</mo><mi>TTR</mi><mo>]</mo><mo>}</mo></mrow></mrow></math></td></tr></table>
<p>
where <span xmlns:mml="http://www.w3.org/1998/Math/MathML"><math id="mm8" overflow="linebreak"><mrow><mrow><msub><mi>K</mi><mi>D</mi></msub></mrow></mrow></math></span> is the dissociation constant. The same experiment was repeated with L55P-TTR and M-TTR.</p></section><section id="sec4dot5-pharmaceuticals-15-00277"><h3 class="pmc_sec_title">4.5. Biophysical Characterization of OleA Emission</h3>
<p>In a first experiment, we prepared two samples with a total volume of 60 µL containing OleA at a concentration of 200 µM, in the presence or in the absence of 200 µM β-cyclodextrin (Sigma-Aldrich, St. Louis, MI, USA). The fluorescence was recorded with the same instrument and cuvette as indicated above. The excitation wavelength was 350 nm; the excitation and emission slits were 5.0 and 10 nm. The traces reported in <a href="#pharmaceuticals-15-00277-f003" class="usa-link">Figure 3</a> are the average of 32 scans at 900 V.</p>
<p>In a second set of experiments, the fluorescence spectra of samples containing OleA at a concentration of 200 µM, dissolved in different solvents, in a total volume of 60 µL were acquired. The solvents (all from Sigma-Aldrich, St. Louis, MI, USA) were water (ε/ε<sub>0</sub> = 80.0), methanol (ε/ε<sub>0</sub> = 32.7), ethanol (ε/ε<sub>0</sub> = 24.5), 1-propanol (ε/ε<sub>0</sub> = 21.8), 1-butanol (ε/ε<sub>0</sub> = 17.5), 1-heptanol (ε/ε<sub>0</sub> = 12.1), and 1-octanol (ε/ε<sub>0</sub> = 10.3). The excitation wavelength was 340 nm; excitation and emission slits were 5.0 nm. The spectra shown in the inset of <a href="#pharmaceuticals-15-00277-f005" class="usa-link">Figure 5</a>b are the average of 16 scans at 950 V. Finally, the fluorescence emitted at 485 nm was measured in samples containing OleA at a concentration of 25 µM, dissolved in water and in the presence of 100 µM wt-TTR, 100 µM bovine serum albumin (BSA, Sigma, St. Louis, MI, USA), or hen egg white lysozyme (HEWL, Sigma, St. Louis, MI, USA). The excitation wavelength was 340 nm; excitation and emission slits were 5.0 nm. The obtained fluorescence values were normalized to the signal recorded in the absence of protein. Each of the values reported in <a href="#pharmaceuticals-15-00277-f003" class="usa-link">Figure 3</a>c is the average of 5 readings. Error bars are SEM.</p></section><section id="sec4dot6-pharmaceuticals-15-00277"><h3 class="pmc_sec_title">4.6. Intrinsic Fluorescence Measurements</h3>
<p>Spectra of wt-TTR, L55P-TTR, and M-TTR intrinsic fluorescence were collected at 295 nm excitation before and after OleA supplementation; the emission intensity was scanned in the 300–400 nm range. The fluorescence emission spectra were normalized to an intensity of 1.0 at the observed peak wavelength using the FL WinLab software (Perkin-Elmer Instrument Corporation, Wellesley, MA, USA) prior to derivatization. Normalization of aromatic residue emission scans was essential to compare the intensities and the positions of the various bands appearing in the second derivatives of the fluorescence emission scans. Five independent spectra were averaged, smoothed with a 15-sliding point sliding window average and a Savitzky–Golay algorithm, and finally, the second derivatives of the smoothed spectra were obtained using Omnic-software (Nicolet Inc., Madison, WI, USA) [<a href="#B50-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B50-pharmaceuticals-15-00277">50</a>]. Such a smoothing step was needed to reduce the noise in the second derivative and designed to meet two main criteria: (i) the overall shape and intensity of the raw emission scan was not affected by the smoothing and (ii) the overall shape of the bands in the second derivative was preserved.</p></section><section id="sec4dot7-pharmaceuticals-15-00277"><h3 class="pmc_sec_title">4.7. Fluorimetric Binding Assays</h3>
<p>Excitation–emission matrices (EEM) were performed in the 280–340 nm excitation range and in the 350–600 nm emission range. The excitation spectra were determined by measuring the emission intensity at a fixed wavelength of 440 nm while varying the excitation wavelength in the 300–400 nm range (5.0 nm by 5.0 nm). For the emission spectra, the excitation was at 360 nm and the emission was monitored in the 380–550 nm range. Fluorescence binding experiments were carried out in 50 mM sodium phosphate buffer, 150 mM sodium chloride, pH 7.4, at 37 °C, using a Perkin Elmer LS-50B spectrofluorometer.</p></section></section><section id="sec5-pharmaceuticals-15-00277"><h2 class="pmc_sec_title">5. Conclusions</h2>
<p>In conclusion, our work provides a combined strategy of molecular docking and fluorescence assays to explore the molecular basis of the mechanism of TTR-OleA binding, with ensuing stabilization of the protein native structure. In addition, a better knowledge of this interaction at the molecular level offers a crucial basis for the use of OleA as a possible preventive and therapeutic agent against various types of TTR amyloidosis. Moreover, protein–polyphenol binding can modify the property of the polyphenol itself, stabilizing the compound and increasing its bioavailability and bioactive functions such as its antioxidant activity [<a href="#B51-pharmaceuticals-15-00277" class="usa-link" aria-describedby="B51-pharmaceuticals-15-00277">51</a>]. Overall, this study suggests that OleA merits consideration for the development of preventives and therapeutics against TTR amyloidosis, contributing to support the importance of a healthy lifestyle, including safe nutrition such as that provided by the Mediterranean diet, rich in plant polyphenols.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>Manuela Leri was supported by Fondazione Umberto Veronesi. We thank MIUR-Italy (“Progetto Dipartimenti di Eccellenza 2018–2022” allocated to Department of Experimental and Clinical Biomedical Sciences “Mario Serio”).</p></section><section id="app1-pharmaceuticals-15-00277" class="app"><h2 class="pmc_sec_title">Supplementary Materials</h2>
<p>The following are available online at <a href="https://www.mdpi.com/article/10.3390/ph15030277/s1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.mdpi.com/article/10.3390/ph15030277/s1</a>, Figure S1: Calculation of the center of mass (COM) and the ratio between the emission at 428 nm and 413 nm of OleA as a function of wt-TTR concentration. Figure S2: Comparison of the emission spectra of OleA in the presence of wt-TTR, L55P-TTR and M-TTR. Figure S3: A phase diagram showing the blue shift of OleA fluorescence upon increasing wt-TTR concentration.</p>
<section class="sm xbox font-sm" id="pharmaceuticals-15-00277-s001"><div class="media p"><div class="caption">
<a href="/articles/instance/8953266/bin/pharmaceuticals-15-00277-s001.zip" data-ga-action="click_feat_suppl" class="usa-link">Click here for additional data file.</a><sup> (333KB, zip) </sup>
</div></div></section></section><section id="notes1"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>Conceptualization, F.B., M.L., M.R. and M.B.; methodology, F.B., M.L. and M.R.; software, F.B., M.L. and M.R.; validation, F.B., M.L. and M.R.; formal analysis, F.B., M.L. and M.R.; investigation, F.B., M.L. and M.R.; data curation, F.B., M.L. and M.R.; writing—original draft preparation, F.B., M.L., M.R. and M.B.; writing—review and editing, F.B., M.L., M.R., M.S. and M.B. All authors have read and agreed to the published version of the manuscript. </p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This work was fully supported by grant of University of Florence (Fondi di Ateneo 2021 to M.B.).</p></section><section id="notes3"><h2 class="pmc_sec_title">Institutional Review Board Statement</h2>
<p>Not applicable.</p></section><section id="notes4"><h2 class="pmc_sec_title">Informed Consent Statement</h2>
<p>Not applicable.</p></section><section id="notes5"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>Data is contained within the article and <a href="#app1-pharmaceuticals-15-00277" class="usa-link">Supplementary Materials</a>.</p></section><section id="notes6"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>The authors declare no conflict of interest.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1"><p><strong>Publisher’s Note:</strong> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="B1-pharmaceuticals-15-00277">
<span class="label">1.</span><cite>Gião T., Saavedra J., Cotrina E., Quintana J., Llop J., Arsequell G., Cardoso I. Undiscovered Roles for Transthyretin: From a Transporter Protein to a New Therapeutic Target for Alzheimer’s Disease. Int. J. Mol. Sci. 2020;21:2075.  doi: 10.3390/ijms21062075.</cite> [<a href="https://doi.org/10.3390/ijms21062075" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7139926/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32197355/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Mol.%20Sci.&amp;title=Undiscovered%20Roles%20for%20Transthyretin:%20From%20a%20Transporter%20Protein%20to%20a%20New%20Therapeutic%20Target%20for%20Alzheimer%E2%80%99s%20Disease&amp;author=T.%20Gi%C3%A3o&amp;author=J.%20Saavedra&amp;author=E.%20Cotrina&amp;author=J.%20Quintana&amp;author=J.%20Llop&amp;volume=21&amp;publication_year=2020&amp;pages=2075&amp;pmid=32197355&amp;doi=10.3390/ijms21062075&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B2-pharmaceuticals-15-00277">
<span class="label">2.</span><cite>Wojtczak A., Cody V., Luft J.R., Pangborn W. Structures of human transthyretin complexed with thyroxine at 2.0 angstrom resolution and 3′,5′-dinitro-N-acetyl-l-thyronine at 2.2 angstrom resolution. Acta Crystallogr. D Biol. Crystallogr. 1996;52:758–765. doi: 10.1107/S0907444996003046.</cite> [<a href="https://doi.org/10.1107/S0907444996003046" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15299640/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Crystallogr.%20D%20Biol.%20Crystallogr.&amp;title=Structures%20of%20human%20transthyretin%20complexed%20with%20thyroxine%20at%202.0%20angstrom%20resolution%20and%203%E2%80%B2,5%E2%80%B2-dinitro-N-acetyl-l-thyronine%20at%202.2%20angstrom%20resolution&amp;author=A.%20Wojtczak&amp;author=V.%20Cody&amp;author=J.R.%20Luft&amp;author=W.%20Pangborn&amp;volume=52&amp;publication_year=1996&amp;pages=758-765&amp;pmid=15299640&amp;doi=10.1107/S0907444996003046&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B3-pharmaceuticals-15-00277">
<span class="label">3.</span><cite>Cendron L., Trovato A., Seno F., Folli C., Alfieri B., Zanotti G., Berni R. Amyloidogenic potential of transthyretin variants insights from structural and computational analyses. J. Biol. Chem. 2009;284:25832–25841. doi: 10.1074/jbc.M109.017657.</cite> [<a href="https://doi.org/10.1074/jbc.M109.017657" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2757985/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19602727/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Biol.%20Chem.&amp;title=Amyloidogenic%20potential%20of%20transthyretin%20variants%20insights%20from%20structural%20and%20computational%20analyses&amp;author=L.%20Cendron&amp;author=A.%20Trovato&amp;author=F.%20Seno&amp;author=C.%20Folli&amp;author=B.%20Alfieri&amp;volume=284&amp;publication_year=2009&amp;pages=25832-25841&amp;pmid=19602727&amp;doi=10.1074/jbc.M109.017657&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B4-pharmaceuticals-15-00277">
<span class="label">4.</span><cite>McCutchen S.L., Lai Z., Miroy G.J., Kelly J.W., Colón W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry. 1995;34:13527–13536. doi: 10.1021/bi00041a032.</cite> [<a href="https://doi.org/10.1021/bi00041a032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7577941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Comparison%20of%20lethal%20and%20nonlethal%20transthyretin%20variants%20and%20their%20relationship%20to%20amyloid%20disease&amp;author=S.L.%20McCutchen&amp;author=Z.%20Lai&amp;author=G.J.%20Miroy&amp;author=J.W.%20Kelly&amp;author=W.%20Col%C3%B3n&amp;volume=34&amp;publication_year=1995&amp;pages=13527-13536&amp;pmid=7577941&amp;doi=10.1021/bi00041a032&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B5-pharmaceuticals-15-00277">
<span class="label">5.</span><cite>Blevins G., Macaulay R., Harder S., Fladeland D., Yamashita T., Yazaki M., Hamidi A.K., Benson M.D., Donat J.R. Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology. 2003;60:1625–1630. doi: 10.1212/01.WNL.0000065901.18353.AB.</cite> [<a href="https://doi.org/10.1212/01.WNL.0000065901.18353.AB" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12771253/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Oculoleptomeningeal%20amyloidosis%20in%20a%20large%20kindred%20with%20a%20new%20transthyretin%20variant%20Tyr69His&amp;author=G.%20Blevins&amp;author=R.%20Macaulay&amp;author=S.%20Harder&amp;author=D.%20Fladeland&amp;author=T.%20Yamashita&amp;volume=60&amp;publication_year=2003&amp;pages=1625-1630&amp;pmid=12771253&amp;doi=10.1212/01.WNL.0000065901.18353.AB&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B6-pharmaceuticals-15-00277">
<span class="label">6.</span><cite>Connors L.H., Lim A., Prokaeva T., Roskens V.A., Costello C.E. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003;10:160–184. doi: 10.3109/13506120308998998.</cite> [<a href="https://doi.org/10.3109/13506120308998998" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14640030/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Tabulation%20of%20human%20transthyretin%20(TTR)%20variants,%202003&amp;author=L.H.%20Connors&amp;author=A.%20Lim&amp;author=T.%20Prokaeva&amp;author=V.A.%20Roskens&amp;author=C.E.%20Costello&amp;volume=10&amp;publication_year=2003&amp;pages=160-184&amp;pmid=14640030&amp;doi=10.3109/13506120308998998&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B7-pharmaceuticals-15-00277">
<span class="label">7.</span><cite>Hagiwara K., Ochi H., Suzuki S., Shimizu Y., Tokuda T., Murai H., Shigeto H., Ohyagi Y., Iwata M., Iwaki T., et al.  Highly selective leptomeningeal amyloidosis with transthyretin variant Ala25Thr. Neurology. 2009;72:1358–1360. doi: 10.1212/WNL.0b013e3181a0fe74.</cite> [<a href="https://doi.org/10.1212/WNL.0b013e3181a0fe74" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19365058/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Highly%20selective%20leptomeningeal%20amyloidosis%20with%20transthyretin%20variant%20Ala25Thr&amp;author=K.%20Hagiwara&amp;author=H.%20Ochi&amp;author=S.%20Suzuki&amp;author=Y.%20Shimizu&amp;author=T.%20Tokuda&amp;volume=72&amp;publication_year=2009&amp;pages=1358-1360&amp;pmid=19365058&amp;doi=10.1212/WNL.0b013e3181a0fe74&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B8-pharmaceuticals-15-00277">
<span class="label">8.</span><cite>Uemichi T., Uitti R.J., Koeppen A.H., Donat J.R., Benson M.D. Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64. Arch. Neurol. 1999;56:1152–1155. doi: 10.1001/archneur.56.9.1152.</cite> [<a href="https://doi.org/10.1001/archneur.56.9.1152" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10488818/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch.%20Neurol.&amp;title=Oculoleptomeningeal%20amyloidosis%20associated%20with%20a%20new%20transthyretin%20variant%20Ser64&amp;author=T.%20Uemichi&amp;author=R.J.%20Uitti&amp;author=A.H.%20Koeppen&amp;author=J.R.%20Donat&amp;author=M.D.%20Benson&amp;volume=56&amp;publication_year=1999&amp;pages=1152-1155&amp;pmid=10488818&amp;doi=10.1001/archneur.56.9.1152&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B9-pharmaceuticals-15-00277">
<span class="label">9.</span><cite>Cardoso I., Almeida M.R., Ferreira N., Arsequell G., Valencia G., Saraiva M.J. Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: Relevance in drug design. Biochem. J. 2007;408:131–138. doi: 10.1042/BJ20070689.</cite> [<a href="https://doi.org/10.1042/BJ20070689" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2049069/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17683281/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochem.%20J.&amp;title=Comparative%20in%20vitro%20and%20ex%20vivo%20activities%20of%20selected%20inhibitors%20of%20transthyretin%20aggregation:%20Relevance%20in%20drug%20design&amp;author=I.%20Cardoso&amp;author=M.R.%20Almeida&amp;author=N.%20Ferreira&amp;author=G.%20Arsequell&amp;author=G.%20Valencia&amp;volume=408&amp;publication_year=2007&amp;pages=131-138&amp;pmid=17683281&amp;doi=10.1042/BJ20070689&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B10-pharmaceuticals-15-00277">
<span class="label">10.</span><cite>Quintas A., Vaz D.C., Cardoso I., Saraiva M.J., Brito R.M. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J. Biol. Chem. 2001;276:27207–27213. doi: 10.1074/jbc.M101024200.</cite> [<a href="https://doi.org/10.1074/jbc.M101024200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11306576/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Biol.%20Chem.&amp;title=Tetramer%20dissociation%20and%20monomer%20partial%20unfolding%20precedes%20protofibril%20formation%20in%20amyloidogenic%20transthyretin%20variants&amp;author=A.%20Quintas&amp;author=D.C.%20Vaz&amp;author=I.%20Cardoso&amp;author=M.J.%20Saraiva&amp;author=R.M.%20Brito&amp;volume=276&amp;publication_year=2001&amp;pages=27207-27213&amp;pmid=11306576&amp;doi=10.1074/jbc.M101024200&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B11-pharmaceuticals-15-00277">
<span class="label">11.</span><cite>Shnyrov V.L., Villar E., Zhadan G.G., Sanchez-Ruiz J.M., Quintas A., Saraiva M.J., Brito R.M. Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin. Biophys. Chem. 2000;88:61–67. doi: 10.1016/S0301-4622(00)00199-X.</cite> [<a href="https://doi.org/10.1016/S0301-4622(00)00199-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11152276/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biophys.%20Chem.&amp;title=Comparative%20calorimetric%20study%20of%20non-amyloidogenic%20and%20amyloidogenic%20variants%20of%20the%20homotetrameric%20protein%20transthyretin&amp;author=V.L.%20Shnyrov&amp;author=E.%20Villar&amp;author=G.G.%20Zhadan&amp;author=J.M.%20Sanchez-Ruiz&amp;author=A.%20Quintas&amp;volume=88&amp;publication_year=2000&amp;pages=61-67&amp;pmid=11152276&amp;doi=10.1016/S0301-4622(00)00199-X&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B12-pharmaceuticals-15-00277">
<span class="label">12.</span><cite>Jiang X., Smith C.S., Petrassi H.M., Hammarstrom P., White J.T., Sacchettini J.C., Kelly J.W. An engineered transthyretin monomer that is non amyloidogenic, unless it is partially denatured. Biochemistry. 2001;40:11442–11452. doi: 10.1021/bi011194d.</cite> [<a href="https://doi.org/10.1021/bi011194d" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11560492/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=An%20engineered%20transthyretin%20monomer%20that%20is%20non%20amyloidogenic,%20unless%20it%20is%20partially%20denatured&amp;author=X.%20Jiang&amp;author=C.S.%20Smith&amp;author=H.M.%20Petrassi&amp;author=P.%20Hammarstrom&amp;author=J.T.%20White&amp;volume=40&amp;publication_year=2001&amp;pages=11442-11452&amp;pmid=11560492&amp;doi=10.1021/bi011194d&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B13-pharmaceuticals-15-00277">
<span class="label">13.</span><cite>Westermark P., Johansson B., Natvig J.B. Senile cardiac amyloidosis: Evidence of two different amyloid substances in the ageing heart. Scand. J. Immunol. 1979;10:303–308. doi: 10.1111/j.1365-3083.1979.tb01355.x.</cite> [<a href="https://doi.org/10.1111/j.1365-3083.1979.tb01355.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/119309/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Scand.%20J.%20Immunol.&amp;title=Senile%20cardiac%20amyloidosis:%20Evidence%20of%20two%20different%20amyloid%20substances%20in%20the%20ageing%20heart&amp;author=P.%20Westermark&amp;author=B.%20Johansson&amp;author=J.B.%20Natvig&amp;volume=10&amp;publication_year=1979&amp;pages=303-308&amp;pmid=119309&amp;doi=10.1111/j.1365-3083.1979.tb01355.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B14-pharmaceuticals-15-00277">
<span class="label">14.</span><cite>Cornwell G.G., 3rd, Murdoch W.L., Kyle R.A., Westermark P., Pitkänen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am. J. Med. 1983;75:618–623. doi: 10.1016/0002-9343(83)90443-6.</cite> [<a href="https://doi.org/10.1016/0002-9343(83)90443-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/6624768/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am.%20J.%20Med.&amp;title=Frequency%20and%20distribution%20of%20senile%20cardiovascular%20amyloid.%20A%20clinicopathologic%20correlation&amp;author=G.G.%20Cornwell&amp;author=W.L.%20Murdoch&amp;author=R.A.%20Kyle&amp;author=P.%20Westermark&amp;author=P.%20Pitk%C3%A4nen&amp;volume=75&amp;publication_year=1983&amp;pages=618-623&amp;pmid=6624768&amp;doi=10.1016/0002-9343(83)90443-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B15-pharmaceuticals-15-00277">
<span class="label">15.</span><cite>Goren H., Steinberg M.C., Farboody G.H. Familial oculoleptomeningeal amyloidosis. Brain. 1980;103:473–495. doi: 10.1093/brain/103.3.473.</cite> [<a href="https://doi.org/10.1093/brain/103.3.473" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7417777/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Brain&amp;title=Familial%20oculoleptomeningeal%20amyloidosis&amp;author=H.%20Goren&amp;author=M.C.%20Steinberg&amp;author=G.H.%20Farboody&amp;volume=103&amp;publication_year=1980&amp;pages=473-495&amp;pmid=7417777&amp;doi=10.1093/brain/103.3.473&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B16-pharmaceuticals-15-00277">
<span class="label">16.</span><cite>Keetch C.A., Bromley E.H., McCammon M.G., Wang N., Christodoulou J., Robinson C.V. L55P transthyretin accelerates subunit exchange and leads to rapid formation of hybrid tetramers. J. Biol. Chem. 2005;280:41667–41674. doi: 10.1074/jbc.M508753200.</cite> [<a href="https://doi.org/10.1074/jbc.M508753200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16219761/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Biol.%20Chem.&amp;title=L55P%20transthyretin%20accelerates%20subunit%20exchange%20and%20leads%20to%20rapid%20formation%20of%20hybrid%20tetramers&amp;author=C.A.%20Keetch&amp;author=E.H.%20Bromley&amp;author=M.G.%20McCammon&amp;author=N.%20Wang&amp;author=J.%20Christodoulou&amp;volume=280&amp;publication_year=2005&amp;pages=41667-41674&amp;pmid=16219761&amp;doi=10.1074/jbc.M508753200&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B17-pharmaceuticals-15-00277">
<span class="label">17.</span><cite>McCutchen S.L., Colon W., Kelly J.W. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry. 1993;32:12119–12127. doi: 10.1021/bi00096a024.</cite> [<a href="https://doi.org/10.1021/bi00096a024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8218290/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Transthyretin%20mutation%20Leu-55-Pro%20significantly%20alters%20tetramer%20stability%20and%20increases%20amyloidogenicity&amp;author=S.L.%20McCutchen&amp;author=W.%20Colon&amp;author=J.W.%20Kelly&amp;volume=32&amp;publication_year=1993&amp;pages=12119-12127&amp;pmid=8218290&amp;doi=10.1021/bi00096a024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B18-pharmaceuticals-15-00277">
<span class="label">18.</span><cite>Sebastião M.P., Saraiva M.J., Damas A.M. The crystal structure of amyloidogenic Leu55 --&gt; Pro transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils. J. Biol. Chem. 1998;273:24715–24722. doi: 10.1074/jbc.273.38.24715.</cite> [<a href="https://doi.org/10.1074/jbc.273.38.24715" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9733771/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Biol.%20Chem.&amp;title=The%20crystal%20structure%20of%20amyloidogenic%20Leu55%20--&gt;%20Pro%20transthyretin%20variant%20reveals%20a%20possible%20pathway%20for%20transthyretin%20polymerization%20into%20amyloid%20fibrils&amp;author=M.P.%20Sebasti%C3%A3o&amp;author=M.J.%20Saraiva&amp;author=A.M.%20Damas&amp;volume=273&amp;publication_year=1998&amp;pages=24715-24722&amp;pmid=9733771&amp;doi=10.1074/jbc.273.38.24715&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B19-pharmaceuticals-15-00277">
<span class="label">19.</span><cite>Obici L., Merlini G. An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert. Opin. Investig. Drugs. 2014;23:1239–1251. doi: 10.1517/13543784.2014.922541.</cite> [<a href="https://doi.org/10.1517/13543784.2014.922541" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25003808/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert.%20Opin.%20Investig.%20Drugs&amp;title=An%20overview%20of%20drugs%20currently%20under%20investigation%20for%20the%20treatment%20of%20transthyretin-related%20hereditary%20amyloidosis&amp;author=L.%20Obici&amp;author=G.%20Merlini&amp;volume=23&amp;publication_year=2014&amp;pages=1239-1251&amp;pmid=25003808&amp;doi=10.1517/13543784.2014.922541&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B20-pharmaceuticals-15-00277">
<span class="label">20.</span><cite>Berk J.L., Suhr O.B., Obici L., Sekijima Y., Zeldenrust S.R., Yamashit T., Heneghan M.A., Gorevic P.D., Litchy W.J., Wiesman J.F., et al.  Repurposing diflunisal for familial amyloid polyneuropathy. A randomized clinical trial. JAMA. 2013;310:2658–2667. doi: 10.1001/jama.2013.283815.</cite> [<a href="https://doi.org/10.1001/jama.2013.283815" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4139164/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24368466/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Repurposing%20diflunisal%20for%20familial%20amyloid%20polyneuropathy.%20A%20randomized%20clinical%20trial&amp;author=J.L.%20Berk&amp;author=O.B.%20Suhr&amp;author=L.%20Obici&amp;author=Y.%20Sekijima&amp;author=S.R.%20Zeldenrust&amp;volume=310&amp;publication_year=2013&amp;pages=2658-2667&amp;pmid=24368466&amp;doi=10.1001/jama.2013.283815&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B21-pharmaceuticals-15-00277">
<span class="label">21.</span><cite>Coelho T., Maia L.F., da Silva A.M., Cruz M.W., Planté-Bordeneuve V., Suhr O.B., Conceiçao I., Schmidt H.H., Trigo P., Kelly J.W., et al.  Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J. Neurol. 2013;260:2802–2814. doi: 10.1007/s00415-013-7051-7.</cite> [<a href="https://doi.org/10.1007/s00415-013-7051-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3825212/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23974642/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Neurol.&amp;title=Long-term%20effects%20of%20tafamidis%20for%20the%20treatment%20of%20transthyretin%20familial%20amyloid%20polyneuropathy&amp;author=T.%20Coelho&amp;author=L.F.%20Maia&amp;author=A.M.%20da%20Silva&amp;author=M.W.%20Cruz&amp;author=V.%20Plant%C3%A9-Bordeneuve&amp;volume=260&amp;publication_year=2013&amp;pages=2802-2814&amp;pmid=23974642&amp;doi=10.1007/s00415-013-7051-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B22-pharmaceuticals-15-00277">
<span class="label">22.</span><cite>Judge D.P., Heitner S.B., Falk R.H., Maurer M.S., Shah S.J., Witteles R.M., Grogan M., Selby V.N., Jacoby D., Hanna M., et al.  Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J. Am. Coll. Cardiol. 2019;74:285–295. doi: 10.1016/j.jacc.2019.03.012.</cite> [<a href="https://doi.org/10.1016/j.jacc.2019.03.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30885685/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Am.%20Coll.%20Cardiol.&amp;title=Transthyretin%20stabilization%20by%20AG10%20in%20symptomatic%20transthyretin%20amyloid%20cardiomyopathy&amp;author=D.P.%20Judge&amp;author=S.B.%20Heitner&amp;author=R.H.%20Falk&amp;author=M.S.%20Maurer&amp;author=S.J.%20Shah&amp;volume=74&amp;publication_year=2019&amp;pages=285-295&amp;pmid=30885685&amp;doi=10.1016/j.jacc.2019.03.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B23-pharmaceuticals-15-00277">
<span class="label">23.</span><cite>Donnelly J.P., Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin. J. Med. 2017;84:12–26. doi: 10.3949/ccjm.84.s3.02.</cite> [<a href="https://doi.org/10.3949/ccjm.84.s3.02" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29257735/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cleve%20Clin.%20J.%20Med.&amp;title=Cardiac%20amyloidosis:%20An%20update%20on%20diagnosis%20and%20treatment&amp;author=J.P.%20Donnelly&amp;author=M.%20Hanna&amp;volume=84&amp;publication_year=2017&amp;pages=12-26&amp;pmid=29257735&amp;doi=10.3949/ccjm.84.s3.02&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B24-pharmaceuticals-15-00277">
<span class="label">24.</span><cite>Adams D., Gonzalez-Duarte A., O’Riordan W.D., Yang C.C., Ueda M., Kristen A.V., Tournev I., Schmidt H.H., Coelho T., Berk J.L., et al.  Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New Engl. J. Med. 2018;379:11–21. doi: 10.1056/NEJMoa1716153.</cite> [<a href="https://doi.org/10.1056/NEJMoa1716153" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29972753/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20Engl.%20J.%20Med.&amp;title=Patisiran,%20an%20RNAi%20therapeutic,%20for%20hereditary%20transthyretin%20amyloidosis&amp;author=D.%20Adams&amp;author=A.%20Gonzalez-Duarte&amp;author=W.D.%20O%E2%80%99Riordan&amp;author=C.C.%20Yang&amp;author=M.%20Ueda&amp;volume=379&amp;publication_year=2018&amp;pages=11-21&amp;pmid=29972753&amp;doi=10.1056/NEJMoa1716153&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B25-pharmaceuticals-15-00277">
<span class="label">25.</span><cite>Trivella D.B., dos Reis C.V., Lima L.M., Foguel D., Polikarpov I. Flavonoid interactions with human transthyretin: Combined structural and thermodynamic analysis. J. Struct. Biol. 2012;180:143–153. doi: 10.1016/j.jsb.2012.07.008.</cite> [<a href="https://doi.org/10.1016/j.jsb.2012.07.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22842046/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Struct.%20Biol.&amp;title=Flavonoid%20interactions%20with%20human%20transthyretin:%20Combined%20structural%20and%20thermodynamic%20analysis&amp;author=D.B.%20Trivella&amp;author=C.V.%20dos%20Reis&amp;author=L.M.%20Lima&amp;author=D.%20Foguel&amp;author=I.%20Polikarpov&amp;volume=180&amp;publication_year=2012&amp;pages=143-153&amp;pmid=22842046&amp;doi=10.1016/j.jsb.2012.07.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B26-pharmaceuticals-15-00277">
<span class="label">26.</span><cite>Bourgault S., Choi S., Buxbaum J.N., Kelly J.W., Price J.L., Reixach N. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem. Biophys. Res. Commun. 2011;410:707–713. doi: 10.1016/j.bbrc.2011.04.133.</cite> [<a href="https://doi.org/10.1016/j.bbrc.2011.04.133" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3145458/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21557933/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochem.%20Biophys.%20Res.%20Commun.&amp;title=Mechanisms%20of%20transthyretin%20cardiomyocyte%20toxicity%20inhibition%20by%20resveratrol%20analogs&amp;author=S.%20Bourgault&amp;author=S.%20Choi&amp;author=J.N.%20Buxbaum&amp;author=J.W.%20Kelly&amp;author=J.L.%20Price&amp;volume=410&amp;publication_year=2011&amp;pages=707-713&amp;pmid=21557933&amp;doi=10.1016/j.bbrc.2011.04.133&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B27-pharmaceuticals-15-00277">
<span class="label">27.</span><cite>Ferreira N., Goncalves N.P., Saraiva M.J., Almeida M.R. Curcumin: A multi-target disease-modifying agent for late-stage transthyretin amyloidosis. Sci. Rep. 2016;6:26623. doi: 10.1038/srep26623.</cite> [<a href="https://doi.org/10.1038/srep26623" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4873750/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27197872/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci.%20Rep.&amp;title=Curcumin:%20A%20multi-target%20disease-modifying%20agent%20for%20late-stage%20transthyretin%20amyloidosis&amp;author=N.%20Ferreira&amp;author=N.P.%20Goncalves&amp;author=M.J.%20Saraiva&amp;author=M.R.%20Almeida&amp;volume=6&amp;publication_year=2016&amp;pages=26623&amp;pmid=27197872&amp;doi=10.1038/srep26623&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B28-pharmaceuticals-15-00277">
<span class="label">28.</span><cite>Ferreira N., Cardoso I., Domingues M.R., Vitorino R., Bastos M., Bai G., Saraiva M.J., Almeida M.R. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett. 2009;583:3569–3576. doi: 10.1016/j.febslet.2009.10.062.</cite> [<a href="https://doi.org/10.1016/j.febslet.2009.10.062" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19861125/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=FEBS%20Lett.&amp;title=Binding%20of%20epigallocatechin-3-gallate%20to%20transthyretin%20modulates%20its%20amyloidogenicity&amp;author=N.%20Ferreira&amp;author=I.%20Cardoso&amp;author=M.R.%20Domingues&amp;author=R.%20Vitorino&amp;author=M.%20Bastos&amp;volume=583&amp;publication_year=2009&amp;pages=3569-3576&amp;pmid=19861125&amp;doi=10.1016/j.febslet.2009.10.062&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B29-pharmaceuticals-15-00277">
<span class="label">29.</span><cite>Leri M., Nosi D., Natalello A., Porcari R., Ramazzotti M., Chiti F., Bellotti V., Doglia S.M., Stefani M., Bucciantini M. The polyphenol Oleuropein aglycone hinders the growth of toxic transthyretin amyloid assemblies. J. Nutr. Biochem. 2016;30:153–166. doi: 10.1016/j.jnutbio.2015.12.009.</cite> [<a href="https://doi.org/10.1016/j.jnutbio.2015.12.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27012632/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Nutr.%20Biochem.&amp;title=The%20polyphenol%20Oleuropein%20aglycone%20hinders%20the%20growth%20of%20toxic%20transthyretin%20amyloid%20assemblies&amp;author=M.%20Leri&amp;author=D.%20Nosi&amp;author=A.%20Natalello&amp;author=R.%20Porcari&amp;author=M.%20Ramazzotti&amp;volume=30&amp;publication_year=2016&amp;pages=153-166&amp;pmid=27012632&amp;doi=10.1016/j.jnutbio.2015.12.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B30-pharmaceuticals-15-00277">
<span class="label">30.</span><cite>Ferreira N., Saraiva M.J., Almeida M.R. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formationn. FEBS Lett. 2011;585:2424–2430. doi: 10.1016/j.febslet.2011.06.030.</cite> [<a href="https://doi.org/10.1016/j.febslet.2011.06.030" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21740906/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=FEBS%20Lett.&amp;title=Natural%20polyphenols%20inhibit%20different%20steps%20of%20the%20process%20of%20transthyretin%20(TTR)%20amyloid%20fibril%20formationn&amp;author=N.%20Ferreira&amp;author=M.J.%20Saraiva&amp;author=M.R.%20Almeida&amp;volume=585&amp;publication_year=2011&amp;pages=2424-2430&amp;pmid=21740906&amp;doi=10.1016/j.febslet.2011.06.030&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B31-pharmaceuticals-15-00277">
<span class="label">31.</span><cite>Corazza A., Verona G., Waudby C.A., Mangione P.P., Bingham R., Uings I., Canetti D., Nocerino P., Taylor G.W., Pepys M.B., et al.  Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes. J. Med. Chem. 2019;62:8274–8283. doi: 10.1021/acs.jmedchem.9b01037.</cite> [<a href="https://doi.org/10.1021/acs.jmedchem.9b01037" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6863598/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31393717/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Med.%20Chem.&amp;title=Binding%20of%20Monovalent%20and%20Bivalent%20Ligands%20by%20Transthyretin%20Causes%20Different%20Short-%20and%20Long-Distance%20Conformational%20Changes&amp;author=A.%20Corazza&amp;author=G.%20Verona&amp;author=C.A.%20Waudby&amp;author=P.P.%20Mangione&amp;author=R.%20Bingham&amp;volume=62&amp;publication_year=2019&amp;pages=8274-8283&amp;pmid=31393717&amp;doi=10.1021/acs.jmedchem.9b01037&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B32-pharmaceuticals-15-00277">
<span class="label">32.</span><cite>Pinho E., Grootveld M., Soares G., Henriques M. Cyclodextrin-based hydrogels toward improved wound dressings. Crit. Rev. Biotechnol. 2014;34:328–337. doi: 10.3109/07388551.2013.794413.</cite> [<a href="https://doi.org/10.3109/07388551.2013.794413" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23919239/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Crit.%20Rev.%20Biotechnol.&amp;title=Cyclodextrin-based%20hydrogels%20toward%20improved%20wound%20dressings&amp;author=E.%20Pinho&amp;author=M.%20Grootveld&amp;author=G.%20Soares&amp;author=M.%20Henriques&amp;volume=34&amp;publication_year=2014&amp;pages=328-337&amp;pmid=23919239&amp;doi=10.3109/07388551.2013.794413&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B33-pharmaceuticals-15-00277">
<span class="label">33.</span><cite>Santoro M.M., Bolen D.W. Unfolding free energy changes determined by the linear extrapolation method. 1. Unfolding of phenylmethanesulfonyl alpha-chymotrypsin using different denaturants. Biochemistry. 1988;27:8063–8068. doi: 10.1021/bi00421a014.</cite> [<a href="https://doi.org/10.1021/bi00421a014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3233195/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Unfolding%20free%20energy%20changes%20determined%20by%20the%20linear%20extrapolation%20method.%201.%20Unfolding%20of%20phenylmethanesulfonyl%20alpha-chymotrypsin%20using%20different%20denaturants&amp;author=M.M.%20Santoro&amp;author=D.W.%20Bolen&amp;volume=27&amp;publication_year=1988&amp;pages=8063-8068&amp;pmid=3233195&amp;doi=10.1021/bi00421a014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B34-pharmaceuticals-15-00277">
<span class="label">34.</span><cite>Pawar A.P., Dubay K.F., Zurdo J., Chiti F., Vendruscolo M., Dobson C.M. Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases. J. Mol. Biol. 2005;350:379–392. doi: 10.1016/j.jmb.2005.04.016.</cite> [<a href="https://doi.org/10.1016/j.jmb.2005.04.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15925383/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Mol.%20Biol.&amp;title=Prediction%20of%20%22aggregation-prone%22%20and%20%22aggregation-susceptible%22%20regions%20in%20proteins%20associated%20with%20neurodegenerative%20diseases&amp;author=A.P.%20Pawar&amp;author=K.F.%20Dubay&amp;author=J.%20Zurdo&amp;author=F.%20Chiti&amp;author=M.%20Vendruscolo&amp;volume=350&amp;publication_year=2005&amp;pages=379-392&amp;pmid=15925383&amp;doi=10.1016/j.jmb.2005.04.016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B35-pharmaceuticals-15-00277">
<span class="label">35.</span><cite>Gazit E. A possible role for pi-stacking in the self-assembly of amyloid fibrils. FASEB J. 2002;16:77–83. doi: 10.1096/fj.01-0442hyp.</cite> [<a href="https://doi.org/10.1096/fj.01-0442hyp" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11772939/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=FASEB%20J.&amp;title=A%20possible%20role%20for%20pi-stacking%20in%20the%20self-assembly%20of%20amyloid%20fibrils&amp;author=E.%20Gazit&amp;volume=16&amp;publication_year=2002&amp;pages=77-83&amp;pmid=11772939&amp;doi=10.1096/fj.01-0442hyp&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B36-pharmaceuticals-15-00277">
<span class="label">36.</span><cite>Porat Y., Mazor Y., Efrat S., Gazit E. Inhibition of islet amyloid polypeptide fibril formation: A potential role for heteroaromatic interactions. Biochemistry. 2004;43:14454–14462. doi: 10.1021/bi048582a.</cite> [<a href="https://doi.org/10.1021/bi048582a" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15533050/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Inhibition%20of%20islet%20amyloid%20polypeptide%20fibril%20formation:%20A%20potential%20role%20for%20heteroaromatic%20interactions&amp;author=Y.%20Porat&amp;author=Y.%20Mazor&amp;author=S.%20Efrat&amp;author=E.%20Gazit&amp;volume=43&amp;publication_year=2004&amp;pages=14454-14462&amp;pmid=15533050&amp;doi=10.1021/bi048582a&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B37-pharmaceuticals-15-00277">
<span class="label">37.</span><cite>Sekijima Y., Kelly J.W., Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr. Pharm. Des. 2008;14:3219–3230. doi: 10.2174/138161208786404155.</cite> [<a href="https://doi.org/10.2174/138161208786404155" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19075702/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr.%20Pharm.%20Des.&amp;title=Pathogenesis%20of%20and%20therapeutic%20strategies%20to%20ameliorate%20the%20transthyretin%20amyloidoses&amp;author=Y.%20Sekijima&amp;author=J.W.%20Kelly&amp;author=S.%20Ikeda&amp;volume=14&amp;publication_year=2008&amp;pages=3219-3230&amp;pmid=19075702&amp;doi=10.2174/138161208786404155&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B38-pharmaceuticals-15-00277">
<span class="label">38.</span><cite>Ge J.F., Qiao J.P., Qi C.C., Wang C.W., Zhou J.N. The binding of resveratrol to monomer and fibril amyloid beta. Neurochem. Int. 2012;61:1192–1201. doi: 10.1016/j.neuint.2012.08.012.</cite> [<a href="https://doi.org/10.1016/j.neuint.2012.08.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22981725/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurochem.%20Int.&amp;title=The%20binding%20of%20resveratrol%20to%20monomer%20and%20fibril%20amyloid%20beta&amp;author=J.F.%20Ge&amp;author=J.P.%20Qiao&amp;author=C.C.%20Qi&amp;author=C.W.%20Wang&amp;author=J.N.%20Zhou&amp;volume=61&amp;publication_year=2012&amp;pages=1192-1201&amp;pmid=22981725&amp;doi=10.1016/j.neuint.2012.08.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B39-pharmaceuticals-15-00277">
<span class="label">39.</span><cite>Yang F.S., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P.P., Kayed R., Glabe C.G., Frautschy S.A., et al.  Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005;280:5892–5901. doi: 10.1074/jbc.M404751200.</cite> [<a href="https://doi.org/10.1074/jbc.M404751200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15590663/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Biol.%20Chem.&amp;title=Curcumin%20inhibits%20formation%20of%20amyloid%20beta%20oligomers%20and%20fibrils,%20binds%20plaques,%20and%20reduces%20amyloid%20in%20vivo&amp;author=F.S.%20Yang&amp;author=G.P.%20Lim&amp;author=A.N.%20Begum&amp;author=O.J.%20Ubeda&amp;author=M.R.%20Simmons&amp;volume=280&amp;publication_year=2005&amp;pages=5892-5901&amp;pmid=15590663&amp;doi=10.1074/jbc.M404751200&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B40-pharmaceuticals-15-00277">
<span class="label">40.</span><cite>Florio P., Folli C., Cianci M., Del Rio D., Zanotti G., Berni R. Transthyretin Binding Heterogeneity and Anti-amyloidogenic Activity of Natural Polyphenols and Their Metabolites. J. Biol. Chem. 2015;290:29769–29780. doi: 10.1074/jbc.M115.690172.</cite> [<a href="https://doi.org/10.1074/jbc.M115.690172" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4705982/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26468275/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Biol.%20Chem.&amp;title=Transthyretin%20Binding%20Heterogeneity%20and%20Anti-amyloidogenic%20Activity%20of%20Natural%20Polyphenols%20and%20Their%20Metabolites&amp;author=P.%20Florio&amp;author=C.%20Folli&amp;author=M.%20Cianci&amp;author=D.%20Del%20Rio&amp;author=G.%20Zanotti&amp;volume=290&amp;publication_year=2015&amp;pages=29769-29780&amp;pmid=26468275&amp;doi=10.1074/jbc.M115.690172&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B41-pharmaceuticals-15-00277">
<span class="label">41.</span><cite>Bezerra F., Saraiva M.J., Almeida M.R. Modulation of the Mechanisms Driving Transthyretin Amyloidosis. Front Mol. Neurosci. 2020;13:592644. doi: 10.3389/fnmol.2020.592644.</cite> [<a href="https://doi.org/10.3389/fnmol.2020.592644" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7759661/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33362465/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Mol.%20Neurosci.&amp;title=Modulation%20of%20the%20Mechanisms%20Driving%20Transthyretin%20Amyloidosis&amp;author=F.%20Bezerra&amp;author=M.J.%20Saraiva&amp;author=M.R.%20Almeida&amp;volume=13&amp;publication_year=2020&amp;pages=592644&amp;pmid=33362465&amp;doi=10.3389/fnmol.2020.592644&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B42-pharmaceuticals-15-00277">
<span class="label">42.</span><cite>Ferreira N., Saraiva M.J., Almeida M.R. Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis. Int. J. Mol. Sci. 2019;20:1287.  doi: 10.3390/ijms20061287.</cite> [<a href="https://doi.org/10.3390/ijms20061287" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6471102/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30875761/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Mol.%20Sci.&amp;title=Uncovering%20the%20Neuroprotective%20Mechanisms%20of%20Curcumin%20on%20Transthyretin%20Amyloidosis&amp;author=N.%20Ferreira&amp;author=M.J.%20Saraiva&amp;author=M.R.%20Almeida&amp;volume=20&amp;publication_year=2019&amp;pages=1287&amp;pmid=30875761&amp;doi=10.3390/ijms20061287&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B43-pharmaceuticals-15-00277">
<span class="label">43.</span><cite>Pullakhandam R., Srinivas P.N.B.S., Nair M.K., Reddy G.B. Binding and stabilization of transthyretin by curcumin. Arch. Biochem. Biophys. 2009;485:115–119. doi: 10.1016/j.abb.2009.02.013.</cite> [<a href="https://doi.org/10.1016/j.abb.2009.02.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19268650/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch.%20Biochem.%20Biophys.&amp;title=Binding%20and%20stabilization%20of%20transthyretin%20by%20curcumin&amp;author=R.%20Pullakhandam&amp;author=P.N.B.S.%20Srinivas&amp;author=M.K.%20Nair&amp;author=G.B.%20Reddy&amp;volume=485&amp;publication_year=2009&amp;pages=115-119&amp;pmid=19268650&amp;doi=10.1016/j.abb.2009.02.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B44-pharmaceuticals-15-00277">
<span class="label">44.</span><cite>Miller M., Pal A., Albusairi W., Joo H., Pappas B., Haque Tuhin M.T., Liang D., Jampala R., Liu F., Khan J., et al.  Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis. J. Med. Chem. 2018;61:7862–7876. doi: 10.1021/acs.jmedchem.8b00817.</cite> [<a href="https://doi.org/10.1021/acs.jmedchem.8b00817" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6276790/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30133284/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Med.%20Chem.&amp;title=Enthalpy-Driven%20Stabilization%20of%20Transthyretin%20by%20AG10%20Mimics%20a%20Naturally%20Occurring%20Genetic%20Variant%20That%20Protects%20from%20Transthyretin%20Amyloidosis&amp;author=M.%20Miller&amp;author=A.%20Pal&amp;author=W.%20Albusairi&amp;author=H.%20Joo&amp;author=B.%20Pappas&amp;volume=61&amp;publication_year=2018&amp;pages=7862-7876&amp;pmid=30133284&amp;doi=10.1021/acs.jmedchem.8b00817&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B45-pharmaceuticals-15-00277">
<span class="label">45.</span><cite>Rigacci S., Guidotti V., Bucciantini M., Parri M., Nediani C., Cerbai E., Stefani M., Berti A. Oleuropein aglycon prevents cytotoxic amyloid aggregation of human amylin. J. Nutr. Biochem. 2010;21:726–735. doi: 10.1016/j.jnutbio.2009.04.010.</cite> [<a href="https://doi.org/10.1016/j.jnutbio.2009.04.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19616928/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Nutr.%20Biochem&amp;title=Oleuropein%20aglycon%20prevents%20cytotoxic%20amyloid%20aggregation%20of%20human%20amylin&amp;author=S.%20Rigacci&amp;author=V.%20Guidotti&amp;author=M.%20Bucciantini&amp;author=M.%20Parri&amp;author=C.%20Nediani&amp;volume=21&amp;publication_year=2010&amp;pages=726-735&amp;pmid=19616928&amp;doi=10.1016/j.jnutbio.2009.04.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B46-pharmaceuticals-15-00277">
<span class="label">46.</span><cite>Mangione P.P., Porcari R., Gillmore J.D., Pucci P., Monti M., Porcari M., Giorgetti S., Marchese L., Raimondi S., Serpell L.C., et al.  Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proc. Natl. Acad. Sci. USA. 2014;111:1539–1544. doi: 10.1073/pnas.1317488111.</cite> [<a href="https://doi.org/10.1073/pnas.1317488111" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3910611/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24474780/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc.%20Natl.%20Acad.%20Sci.%20USA&amp;title=Proteolytic%20cleavage%20of%20Ser52Pro%20variant%20transthyretin%20triggers%20its%20amyloid%20fibrillogenesis&amp;author=P.P.%20Mangione&amp;author=R.%20Porcari&amp;author=J.D.%20Gillmore&amp;author=P.%20Pucci&amp;author=M.%20Monti&amp;volume=111&amp;publication_year=2014&amp;pages=1539-1544&amp;pmid=24474780&amp;doi=10.1073/pnas.1317488111&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B47-pharmaceuticals-15-00277">
<span class="label">47.</span><cite>Trott O., Olson A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010;31:455–461. doi: 10.1002/jcc.21334.</cite> [<a href="https://doi.org/10.1002/jcc.21334" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3041641/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19499576/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Comput.%20Chem.&amp;title=AutoDock%20Vina:%20Improving%20the%20speed%20and%20accuracy%20of%20docking%20with%20a%20new%20scoring%20function,%20efficient%20optimization,%20and%20multithreading&amp;author=O.%20Trott&amp;author=A.J.%20Olson&amp;volume=31&amp;publication_year=2010&amp;pages=455-461&amp;pmid=19499576&amp;doi=10.1002/jcc.21334&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B48-pharmaceuticals-15-00277">
<span class="label">48.</span><cite>Morais-de-Sá E., Neto-Silva R.M., Pereira P.J., Saraiva M.J., Damas A.M. The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin. Acta Crystallogr. D Biol. Crystallogr. 2006;62:512–519. doi: 10.1107/S0907444906006962.</cite> [<a href="https://doi.org/10.1107/S0907444906006962" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16627944/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Crystallogr.%20D%20Biol.%20Crystallogr.&amp;title=The%20binding%20of%202,4-dinitrophenol%20to%20wild-type%20and%20amyloidogenic%20transthyretin&amp;author=E.%20Morais-de-S%C3%A1&amp;author=R.M.%20Neto-Silva&amp;author=P.J.%20Pereira&amp;author=M.J.%20Saraiva&amp;author=A.M.%20Damas&amp;volume=62&amp;publication_year=2006&amp;pages=512-519&amp;pmid=16627944&amp;doi=10.1107/S0907444906006962&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B49-pharmaceuticals-15-00277">
<span class="label">49.</span><cite>Sterling T., Irwin J.J. ZINC 15--Ligand Discovery for Everyone. J. Chem. Inf. Model. 2015;55:2324–2337. doi: 10.1021/acs.jcim.5b00559.</cite> [<a href="https://doi.org/10.1021/acs.jcim.5b00559" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4658288/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26479676/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Chem.%20Inf.%20Model.&amp;title=ZINC%2015--Ligand%20Discovery%20for%20Everyone&amp;author=T.%20Sterling&amp;author=J.J.%20Irwin&amp;volume=55&amp;publication_year=2015&amp;pages=2324-2337&amp;pmid=26479676&amp;doi=10.1021/acs.jcim.5b00559&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B50-pharmaceuticals-15-00277">
<span class="label">50.</span><cite>Kumar V., Sharma V.K., Kalonia D.S. Second derivative tryptophan fluorescence spectroscopy as a tool to characterize partially unfolded intermediates of proteins. Int. J. Pharm. 2005;294:193–199. doi: 10.1016/j.ijpharm.2005.01.024.</cite> [<a href="https://doi.org/10.1016/j.ijpharm.2005.01.024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15814244/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Pharm.&amp;title=Second%20derivative%20tryptophan%20fluorescence%20spectroscopy%20as%20a%20tool%20to%20characterize%20partially%20unfolded%20intermediates%20of%20proteins&amp;author=V.%20Kumar&amp;author=V.K.%20Sharma&amp;author=D.S.%20Kalonia&amp;volume=294&amp;publication_year=2005&amp;pages=193-199&amp;pmid=15814244&amp;doi=10.1016/j.ijpharm.2005.01.024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B51-pharmaceuticals-15-00277">
<span class="label">51.</span><cite>Frazier R.A., Papadopoulou A., Mueller-Harvey I., Kissoon D., Green R.J. Probing protein-tannin interactions by isothermal titration microcalorimetry. J. Agric. Food Chem. 2003;51:5189–5195. doi: 10.1021/jf021179v.</cite> [<a href="https://doi.org/10.1021/jf021179v" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12926857/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Agric.%20Food%20Chem.&amp;title=Probing%20protein-tannin%20interactions%20by%20isothermal%20titration%20microcalorimetry&amp;author=R.A.%20Frazier&amp;author=A.%20Papadopoulou&amp;author=I.%20Mueller-Harvey&amp;author=D.%20Kissoon&amp;author=R.J.%20Green&amp;volume=51&amp;publication_year=2003&amp;pages=5189-5195&amp;pmid=12926857&amp;doi=10.1021/jf021179v&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/8953266/bin/pharmaceuticals-15-00277-s001.zip" data-ga-action="click_feat_suppl" class="usa-link">Click here for additional data file.</a><sup> (333KB, zip) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Data is contained within the article and <a href="#app1-pharmaceuticals-15-00277" class="usa-link">Supplementary Materials</a>.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Pharmaceuticals are provided here courtesy of <strong>Multidisciplinary Digital Publishing Institute  (MDPI)</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.3390/ph15030277"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/pharmaceuticals-15-00277.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (3.1 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/8953266/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/8953266/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC8953266%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC8953266/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC8953266/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC8953266/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/35337074/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC8953266/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/35337074/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC8953266/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/8953266/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="EfRxCYpgKYKJ8wWBSmSPWZKsxafja0EyFYEe5JNsHkZfsZfW6AXvKDc2iYvTNAlc">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
        <script type="module" crossorigin="" src="/static/assets/math-574fdcc6.js"></script>
    
    

    </body>
</html>
